The QualityStocks Daily Thursday, January 12th, 2023

Today's Top 3 Investment Newsletters

Schaeffer's(BBAI) $3.0500 +260.48%

QualityStocks(ARVL) $0.5400 +100.00%

The Stock Dork(KERN) $1.6500 +66.67%

The QualityStocks Daily Stock List

Arrival SA (ARVL)

InvestorPlace, Schaeffer's, StocksEarning, MarketBeat, Trades Of The Day, The Stock Dork and QualityStocks reported earlier on Arrival SA (ARVL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Arrival SA (NASDAQ: ARVL) (FRA: 47K) is a technology company which is focused on designing, assembling and distributing commercial electric vehicles.

The firm has its headquarters in Howald, Luxembourg and was incorporated in 2015. It serves consumers and automotive industries around the globe.

The company’s mission is to make air clean through the replacement of all cars with more affordable electric alternatives. It is reinventing the design as well as the production of electric cars for end-to-end sustainability. It develops technologies for electric vehicles with local scalable micro-factories combined with proprietary in-house developed composite materials, software and components. This technique helps governments and cities achieve their sustainability goals and supercharges their communities.

The enterprise’s products and processes are equitable, sustainable, desirable and zero-emission, and help deliver the radical impact the world needs to fight the worst effects of the climate crisis. Its portfolio of electric vehicles includes EV buses, cars and vans known as the Arrival Van, the Arrival Bus and the Arrival Car. It also develops Generation 2 Electric Vehicles that are assembled using small footprint micro-factories. The enterprise’s products make roads safer for everyone using strong, lightweight and low cost materials. It also provides solutions related to fintech, mobility, automotive, supply chain, product, technology and other services.

The company remains focused on partnering with operators, cities and governments to build seamless mobility services and infrastructure solutions for communities to help them meet their clean energy targets. These partnerships not only extend the company’s consumer reach but will also bring in additional revenue into the company.

Arrival SA (ARVL), closed Thursday's trading session at $0.54, up 100%, on 93,597,898 volume. The average volume for the last 3 months is 22.575M and the stock's 52-week low/high is $0.1411/$7.315.

Bakkt Holdings (BKKT)

Schaeffer's, StocksEarning, QualityStocks, InvestorPlace, MarketBeat, Trades Of The Day, The Online Investor and Daily Trade Alert reported earlier on Bakkt Holdings (BKKT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Bakkt Holdings Inc. (NYSE: BKKT) is a digital asset marketplace which allows consumers to sell, buy, store and spend digital assets.

The firm has its headquarters in Atlanta, Georgia and was incorporated in 2018. Prior to its name change, the firm was known as VPC Impact Acquisition Holdings. The firm serves consumers around the globe.

The company’s mission is to power commerce by re-imagining the digital asset ecosystem. It operates as a subsidiary of Intercontinental Exchange Holdings Inc.

The enterprise allows consumers to transact and view their digital assets in one place. Its retail platform, the Bakkt platform, has been designed with an agile and scalable architecture that can support additional digital assets. The platform decreases payment costs, amplifies consumer spending and supports loyalty programs, adding value for all its key stakeholders in the digital assets ecosystem. The platform also allows brands and merchants to create compelling experiences to engage existing customers and attract new ones. Its business offerings include powering loyalty programs, crypto rewards, crypto services and digital assets payments. The enterprise’s institutions offerings include crypto derivatives and crypto custody. Its digital asset market includes miles, loyalty points, gift cards and cryptocurrencies.

The company recently entered into a partnership with Nexo, a leading regulated digital assets institution. This agreement will allow the company to expand its network of revenue and operations while building upon its partnerships with other businesses, which will encourage more investments into the company and boost its growth.

Bakkt Holdings (BKKT), closed Thursday's trading session at $2.78, up 94.4056%, on 25,145,552 volume. The average volume for the last 3 months is 2.228M and the stock's 52-week low/high is $1.13/$9.01.

HTG Molecular Diagnostics (HTGM)

StockMarketWatch, TraderPower, MarketClub Analysis, BUYINS.NET, QualityStocks, MarketBeat,, Promotion Stock Secrets, StockOodles, The Street, Schaeffer's, Wall Street Mover, AllPennyStocks, PennyStockScholar, OTCtipReporter, Money Morning, StreetInsider, The Online Investor, INO Market Report, TopPennyStockMovers and reported earlier on HTG Molecular Diagnostics (HTGM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

HTG Molecular Diagnostics Inc. (NASDAQ: HTGM) (FRA: 65HA) is a life sciences firm that is focused on the advancement of precision medicine via innovative profiling technology designed to hasten discovery of new drug candidates and develop diagnostics.

The firm has its headquarters in Tucson, Arizona and was incorporated in October 1997 by Bruce E. Seligmann. Prior to its name change in March 2011, the firm was known as HTG Inc. It operates as part of the diagnostics and research industry, under the healthcare sector. The firm serves consumers around the world, with a focus on Europe and the United States.

The enterprise is party to an agreement with QIAGEN Manchester Ltd. The enterprise provides assay kits, software which automates processing of samples and profiles for different molecular targets, and instruments. Its molecular profiling panels include the mRNA tumor response panel; the immune response panel; the EdgeSeq ALKPlus assay EU; the EdgeSeq Oncology Biomarker panel; the DLBCL cell of origin assay; the miRNA whole-transcriptome assay; and the Transcriptome Panel. The enterprise distributes its consumables and instruments directly in Europe and the U.S., as well as via distributors in various parts of Europe and internationally. It serves biopharmaceutical firms, molecular testing laboratories and academic research centers.

The company recently expanded its therapeutics team with the addition of an experienced program leader in drug discovery and development. This move will bolster its efforts to introduce new therapeutic candidates to the market, which will benefit patients with various indications and bring in more revenues into the company as well.

HTG Molecular Diagnostics (HTGM), closed Thursday's trading session at $4.76, up 32.9609%, on 2,468,496 volume. The average volume for the last 3 months is 67.4M and the stock's 52-week low/high is $2.3844/$51.12.

Marathon Patent Group, Inc. (MARA)

InvestorPlace, MarketClub Analysis, Schaeffer's, QualityStocks, StockMarketWatch, MarketBeat, TradersPro, StocksEarning,, The Online Investor, BUYINS.NET, Trades Of The Day, The Street,, TraderPower, Daily Trade Alert, Wall Street Mover, PoliticsAndMyPortfolio, TopPennyStockMovers, INO Market Report, FeedBlitz, Kiplinger Today, Wealth Insider Alert, StreetAuthority Daily, Barchart, DreamTeamNetwork, InvestorsUnderground, RedChip, AllPennyStocks, Stock Analyzer, Stock Beast, StockOodles, Street Insider, StreetInsider and Promotion Stock Secrets reported earlier on Marathon Patent Group, Inc. (MARA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Marathon Patent Group, Inc. is one of the few Nasdaq listed cryptocurrency mining companies in the United States. A Digital Asset Company, it mines cryptocurrencies, with an emphasis on the blockchain ecosystem and the generation of digital assets. At present, Marathon Patent Group operates one mining facility in the Province of Quebec.

The Company previously went by the name American Strategic Minerals Corporation. It changed its name to Marathon Patent Group, Inc. in February of 2013. Established in 2010, Marathon Patent Group is headquartered in Las Vegas, Nevada. The Company lists on the Nasdaq Global Select Market.

BlockMaintain is a Partner of Marathon Patent Group. BlockMaintain provides fully-managed mining solutions on its strong proprietary infrastructure. Its advantage is in its custom software and mining innovations. All mining activities are automated and optimized through its smart mining software. BlockMaintain serves mining operations at all iterations. This is from phase one through advanced profitable mining.

Marathon Patent Group, Inc. (MARA), closed Thursday's trading session at $7.03, up 30.9125%, on 67,399,979 volume. The average volume for the last 3 months is 41,894 and the stock's 52-week low/high is $3.11/$32.74.

TerrAscend Corp. (TRSSF)

MarketBeat, QualityStocks, CFN Media Group, Top Pros' Top Picks, Profit Trends, Wealth Insider Alert, TradersPro, The Online Investor, StreetAuthority Daily and Daily Trade Alert reported earlier on TerrAscend Corp. (TRSSF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

TerrAscend Corp (OTCQX: TRSSF) (CNSX: TER) (FRA: TED) is a company involved in the cultivation, processing and sale of medical and adult-use marijuana.

The firm has its headquarters in Mississauga, Canada and was incorporated in 2017, on March 7th by Michael Nashat, Vijay Sappani and Basem Hanna. It operates as part of the drug manufacturers-specialty and generic industry, under the healthcare sector. The firm serves consumers in the United States and Canada.

The company is focused on creating and delivering quality cannabis products and services that meet the evolving needs of patients. It owns several synergistic businesses and brands, including The Apothecarium, Gage Cannabis, Prism, Kind Tree, State Flower, Ilera Healthcare, Arise Bioscience Inc. and Valhalla Confections. Arise Bioscience Inc. is a manufacturer and distributor of hemp-derived products. Gage is a cannabis brand and operator that provides cannabis products to consumers in the state of Michigan and Canada. Ilera Healthcare is a medical cannabis cultivator, processor and dispenser.

The enterprise manufactures cannabis-infused artisan edibles; and produces and distributes hemp-derived wellness products to retail locations. It operates in Pennsylvania, New Jersey, Michigan and California, with licensed cultivation and processing operations in Maryland and licensed production in Canada. As of July 26, 2022, the company operated 27 dispensaries, including 3 Cookies dispensaries in Michigan and one in Toronto.

The firm recently launched a new cannabis-provisioning center in Michigan. This move not only helps extend the firm’s consumer reach in the United States and helps to better meet the needs of consumers in the state but will also generate additional revenues.

TerrAscend Corp. (TRSSF), closed Thursday's trading session at $1.53, up 4.7945%, on 41,894 volume. The average volume for the last 3 months is 8,533 and the stock's 52-week low/high is $1.00/$6.07.

ASP Isotopes (ASPI)

We reported earlier on ASP Isotopes (ASPI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

ASP Isotopes Inc. (NASDAQ: ASPI) is a pre-commercial stage advanced materials firm that is focused on developing and commercializing isotopes.

The firm has its headquarters in Boca Raton, Florida and was incorporated in 2021, on September 13th by Robert Ainscow and Paul E. Mann. It operates as part of the chemicals industry, under the basic materials sector. The firm serves consumers around the globe.

The company operates primarily through subsidiaries: ASP Isotopes Guernsey Ltd, ASP Isotopes UK Limited and Enriched Energy LLC. ASP Isotopes Guernsey Ltd is involved in developing and commercializing high value, low volume isotopes for specialized end markets (like Mo-100 and Silicon-28) while ASP Isotopes UK Ltd is a licensee of the ASP technology under the exclusive license agreement with Klydon Proprietary Ltd. On the other hand, Enriched Energy LLC is focused on the development and commercialization of uranium for the nuclear energy market.

The enterprise’s technology allows it to enrich elements with both low and high atomic masses. It produces and commercializes enriched Molybdenum-100 (Mo-100), a non-radioactive isotope for the medical industry. It also intends to use the ASP technology licensed to produce enriched Uranium-235 (U-235), an isotope of uranium for the carbon-free energy industry.

The firm recently entered into a 25-year supply agreement with BRICEM for highly enriched Mo-100. This agreement will not only bring in additional revenues into the firm but also open it up to new growth and investment opportunities, which will positively influence its growth.

ASP Isotopes (ASPI), closed Thursday's trading session at $1.64, off by 0.906344%, on 8,542 volume. The average volume for the last 3 months is 100,497 and the stock's 52-week low/high is $1.25/$3.75.

Erayak Power Solution Group (RAYA)

We reported earlier on Erayak Power Solution Group (RAYA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Erayak Power Solution Group Inc. (NASDAQ: RAYA) is a holding firm that is focused on the research and development, manufacture, retail and wholesale of power solution products.

The firm has its headquarters in Wenzhou, China and was incorporated in 2009. It operates as part of the electrical equipment and parts industry, under the industrials sector. The firm serves consumers around the globe, with a focus on those in the People’s Republic of China.

The company operates as a subsidiary of Erayak International Limited. It makes an important contribution to building convenient mobile life globally, in addition to making significant investments in future technologies such as artificial intelligence, the industrial internet of things (IIoT), and cloud solutions. The company is focused on consistently aligning business performance with the specific needs of its clients in the Mobile Power Related Fields, Technology Systems and Global Aftersales System. It operates through the China, France, Poland, Germany, the United Kingdom and Mexico geographical segments.

The enterprise’s product portfolio includes sine wave and off-grid inverters, inverter and gasoline generators, battery and smart chargers, and custom-designed products. Its products are used in recreational vehicles, agricultural and industrial vehicles, electrical appliances, and outdoor living products.

The company, whose latest financial results show significant increases in generator sales, remains focused on increasing its production capacity to help launch dual-fuel generators, hybrid inverters and upgraded gasoline generators to meet the expected increase in energy demand from Europe. This will positively influence its revenues as well as its overall growth.

Erayak Power Solution Group (RAYA), closed Thursday's trading session at $2.49, up 2.0492%, on 100,497 volume. The average volume for the last 3 months is 25,390 and the stock's 52-week low/high is $1.72/$3.8864.

Elementis (EMNSF)

MarketBeat, Trades Of The Day and Daily Trade Alert reported earlier on Elementis (EMNSF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Elementis Plc (OTC: EMNSF) (LON: ELM) (FRA: E3E) is a specialty chemical firm that manufactures specialty chemicals.

The firm has its headquarters in London, the United Kingdom and was incorporated in 1844. It operates as part of the specialty chemicals industry, under the basic materials sector. The firm serves consumers around the globe, with a focus on those in the United Kingdom, the rest of Europe and North America.

The enterprise operates through the Personal Care, Talc, Coatings and Chromium segments. The Personal Care segment produces and sells rheological modifiers and compounded products for antiperspirants/deodorants, color cosmetics, bath and soap, and hair and skin care products. The Talc segment produces and supplies talc for use in paints and coatings, plastics, food and pharmaceuticals, polyester putties, ceramics, paper and pulp sectors. On the other hand, the Coatings segment produces and sells rheological modifiers and additives for industrial finishes, construction, architectural coatings, adhesives and sealants, colorant dispersions, inks and specialty applications; and bentonite and hectorite clays, as well as polymer-based additives used in drilling, simulation, and cementing applications. The Chromium segment produces chromium chemicals, such as chromic acid, chromic oxide, chrome sulfate, sodium sulfate and sodium dichromate for use in pigments, cosmetics, chrome metal production, refractories, metal and plastic finishing, wood treatment, leather tanning, trivalent metal finishing, coatings, and metal passivation, as well as for making detergents, glasses, papers, and starches. It also offers personal care products, waxes, additives and resins, organoclays, colorants, and other specialty additives.

The company remains focused on finding innovation opportunities that will enhance its clients’ performance. This will bring in additional revenues into the company while also bolstering its overall growth.

Elementis (EMNSF), closed Thursday's trading session at $1.44, even for the day. The average volume for the last 3 months is 10.524M and the stock's 52-week low/high is $1.00/$2.04.

Greenidge Generation Holdings (GREE)

InvestorPlace, Trades Of The Day, Real Pennies, MarketBeat and Daily Trade Alert reported earlier on Greenidge Generation Holdings (GREE), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Greenidge Generation Holdings Inc. (NASDAQ: GREE) is an integrated cryptocurrency datacenter and power generation firm that mines cryptocurrencies.

The firm has its headquarters in Fairfield, Connecticut and was incorporated in 1937. It operates as part of the capital markets industry, under the financial services sector. The firm serves consumers around the globe.

The company’s mission is to be exceptional stewards in three areas – energy, environment, and economic growth. It operates in two locations; the Town of Torrey, New York and Spartanburg, South Carolina, through the Cryptocurrency Datacenter and Power Generation Segment and the Support Services business segment. Its Support Services segment comprises of the business and offers customer and technical support solutions delivered by home-based employees. The company’s home sourcing model has been specifically designed for remote work, with attention to security, recruiting, training, delivery, and employee engagement. Cryptocurrency data center operations generate revenue by earning bitcoin as rewards and transaction fees for supporting the global bitcoin network with application-specific integrated circuit computers (ASICs or miners).

The enterprise owns and operates a 106 MW power generation facility that is connected to the New York Independent Systems Operator (the NYISO) which operates New York State’s power grid. It sells capacity, energy, and ancillary services to the wholesale power grid managed by the NYISO.

The firm, which recently gave an update on its operations, remains focused on finding strategic opportunities that will help generate value for its shareholders and bolster its overall growth.

Greenidge Generation Holdings (GREE), closed Thursday's trading session at $1.06, up 61.5607%, on 10,524,202 volume. The average volume for the last 3 months is 2.628M and the stock's 52-week low/high is $0.2202/$16.6399.

Peabody Energy Corporation (BTU)

The Online Investor, The Street, MarketClub Analysis, StreetInsider, Schaeffer's, InvestorPlace, Daily Wealth, MarketBeat, SmarTrend Newsletters, The Growth Stock Wire, QualityStocks, Money Morning, Hit and Run Candle Sticks, Daily Markets, Barchart, TheStockAdvisors, StreetAuthority Daily, TheStockAdvisor, TopStockAnalysts, TradersPro, Energy and Capital, Daily Trade Alert, BUYINS.NET,, Wealth Daily, Kiplinger Today, SmallCap Network, SureMoney, Zacks, WStreet Market Commentary, Street Insider, Wall Street Daily, ProfitableTrading, Forbes, Trading Concepts, The Motley Fool, Investment House, Investing Futures, The Wealth Report, Trades Of The Day, Market Report, Dividend Opportunities, Uncommon Wisdom, Dynamic Wealth Report, Investment U, Investors Alley, Wyatt Investment Research, TradingMarkets, StrategicTechInvestor, Trade of the Week, The Tycoon Report, Money and Markets, Top Pros' Top Picks, Stock Tips Network, FNNO Newsletters, Stockhouse, StockMarketWatch, StockTwits, Stock Gumshoe, Daily Stocks, Inside Investing Daily, Wealthpire Inc., Cabot Wealth, The Trading Report, Wall Street Elite, Trading Markets, Stock Beast, Investing Daily, AllPennyStocks, TheTradingReport, Today's Financial News, InvestmentHouse, Investopedia, InvestorGuide, SmallCapNetwork, Market Authority, Market Intelligence Center, Market Intelligence Center Alert, Top Stock Picks and INO Market Report reported earlier on Peabody Energy Corporation (BTU), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Advances in automated technology have improved safety in underground coal mining significantly, removing even more miners from possibly dangerous situations. Resources Safety and Health Queensland found that in the last five years, 356 severe incidents occurred in both underground and surface coal mines in Queensland with 10 individuals losing their lives as a result.

The advanced technology, called ExScan, was developed by the Commonwealth Scientific & Industrial Research Organization (CSIRO) in collaboration with the Australian Coal Industry’s Research Program, which financed the project. CSIRO is an Australian government agency involved in scientific research.

The technology in question uses 3D lasers to map tunnels, cavities and voids underground in real time. In mines, it scans longwalls to help produce coal, without workers having to go underground or work next to heavy machinery.

A senior principal research engineer at CSIRO, Dr. Mark Dunn, revealed that the technology afforded operators a view of what was underground without having to visit the site.

ExScan was first used in a trial at a mine located in the northern region of Blackwater in central Queensland a few years ago. Following its success, ExScan was adopted for use in at least 10 mines across Australia as well as in other countries, including the United States.

Michael Condie, an automation coordinator at the Oaky Creek mine owned by Glencore, stated that remote mining of the longwall was an objective of underground mining and assisted in the production of metallurgical coal. Condie revealed that this technology allows him to mine coal with the click of a button.

Duane Witkowski, an automation engineer, revealed that the advancements made in technology that enabled automated mining were not something he imagined would happen when he started out in the industry decades ago.

Dunn also highlighted the need for safety, noting that one of the primary objectives in their mining research and advances was to ensure that there were no operators working underground in mines in the next few years. He added that getting the utilities and tools adopted by the industry was crucial to improving safety.

Dunn then revealed that the technology was being trialed in the civil engineering industry space and, in particular, tunneling as well as in open-cut mines. He noted that this technology could be useful in other environments, and there would always be need for remote operations systems as the presence of any technologies or sensors that could help people control equipment in possibly dangerous environments would always be valuable.

As these technologies get widespread adoption among the major coal miners such as Peabody Energy Corporation (NYSE: BTU), accidents in coal mining will be few and far between due to the enhanced safety of all mining operations.

Peabody Energy Corporation (BTU), closed Thursday's trading session at $27.73, up 2.1363%, on 2,664,892 volume. The average volume for the last 3 months is 1.25M and the stock's 52-week low/high is $9.83/$33.29.

Mind Medicine Inc. (MNMD)

InvestorPlace, Schaeffer's, QualityStocks, The Wealth Report, The Street, MarketBeat, The Stock Dork, MarketClub Analysis, Daily Trade Alert and Trades Of The Day reported earlier on Mind Medicine Inc. (MNMD), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Psychedelics have become increasingly popular, with more studies finding that the substances may have therapeutic benefits for a range of mental health disorders. While this is positive, their adoption into mainstream media also increases the risk of teens consuming these drugs in the name of experimentation.

For example, data from a 2021 survey conducted by the University of Michigan found that roughly 10% of 8th graders, 19% of 10th graders and more than 30% of 12th graders has used illegal drugs in the last year. A separate survey by NIDA also found that a percentage of teens had consumed MDMA, LSD and ketamine in the past year and felt it would be easy to obtain cocaine.

So, how can you talk to your teenage children about psychedelics and other drugs?

For starters, you’ll want to initiate a casual conversation about these drugs with your teen. This will allow you to connect with your child and also learn how much they know about these drugs.

Keep in mind that teenagers have a short attention span so a one-hour conversation may not be the best fit. Additionally, you should ensure that you listen and ask questions as teens sometimes feign familiarity to act mature.

If you do discover that your child may have experimented with the drugs, scolding will not help. Instead, focus on harm reduction as this reduces the severity of the risks associated with drug use. You can start by encouraging them to be safe and talk about safe dosages, as high psychedelic doses may cause bad trips.

You can also highlight the importance of knowing the source of a drug before consuming it. If a source cannot be verified, advise your child to refrain from consumption as some drugs may be laced with fentanyl. Fentanyl is a potent synthetic opioid analgesic that is classified as a Schedule II prescription drug.

One can reduce the risk of an accidental fentanyl overdose by testing using fentanyl testing strips. This may just save their lives. In the event of an overdose, a Narcan kit will save a life. These contain Naloxone-filled needles that reverse the effects of an opioid overdose when injected.

When having a conversation with your child about these drugs, encourage them to call home even if they are intoxicated. You not only provide a safe space for them but also make them more comfortable with being open with you.

Here are some resources you can use as you consider this conversation:

It is also important to emphasize that nearly all industry actors, including Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), are focused on developing formulations to be used in clinical settings and not for recreational purposes, which is testament to how potent these substances can be.

Mind Medicine Inc. (MNMD), closed Thursday's trading session at $3.11, up 6.8729%, on 1,263,326 volume. The average volume for the last 3 months is 7.663M and the stock's 52-week low/high is $2.12/$22.20.

Atlis Motor Vehicles Inc. (AMV)

The Stock Dork, QualityStocks and MarketBeat reported earlier on Atlis Motor Vehicles Inc. (AMV), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

By 2030, Europe is anticipated to surpass China as the region with the highest use of electric vehicles globally. According to the Citi State of Global Electric Vehicle Adoption report, Europe is predicted to grow its market share for EVs from its current level of 22% to 67.3%, taking the lead against China’s 66.6%, South Korea’s 60.5%, the United States’ 45.8%, and the Middle East and Africa, predicted at 2.7%.

In October, the parliament and the council in Europe came to an agreement that guarantees all newly purchased cars as well as vans registered in Europe will be fully electric by 2035, which raises concerns about hybrid-tech that has long been relevant in Europe and denotes a complete ban on gasoline-powered vehicles in 15 years.

In the last year, EVs have become more and more popular in the region, taking about 17% of the market and surpassing diesel-powered cars to take second place behind gasoline-powered cars in terms of popularity according to SMMT data in the United Kingdom. This will continue to rise as gasoline and diesel-powered cars and vans won’t be sold in the UK after 2030.

The Citi report shows that 2022 was considered the best year for the adoption of EVs in the United States. In December alone, BEVs claimed 33% of the market, which was the category’s highest ever market share per month, thanks in large part to the delivery of numerous Tesla vehicles as well as the entry of new vehicle sales, which increased over the course of the year to over 5% of all sales of light vehicles.

Even though the automakers implemented price hikes, there was still a rise in the adoption of electric vehicles. Nonetheless, eight states in the United States accounted for two-thirds of the total sales made from electric vehicles. According to the report by Citi, an unexpected increase in demand for electric vehicles could be coming to the United States. Nonetheless, the economic slump may have unexpected effects on the United States’ adoption of electric vehicles.

In California, sales of electric vehicles make up 35% of all U.S. sales, and this could well be impacted by recent technology layoffs. This is especially true given that a younger demographic is supporting demand.

As reported by Citi, new battery tech as well as the capacity to introduce huge quantities of electric vehicles at lower prices will determine the rise in the use of electric vehicles in the future. The efforts being made by companies such as Atlis Motor Vehicles Inc. (NASDAQ: AMV) to make fully electric work trucks will also be beneficial for the electrification of specialized industries, including agriculture.

Atlis Motor Vehicles Inc. (AMV), closed Thursday's trading session at $6.52, off by 35.3175%, on 7,662,518 volume. The average volume for the last 3 months is 664,125 and the stock's 52-week low/high is $2.26/$243.99.

The QualityStocks Company Corner

Vision Energy Corp. (OTCQB: VENG)

The QualityStocks Daily Newsletter would like to spotlight Vision Energy Corp. (OTCQB: VENG).

Vision Energy is pioneering a Green Energy Hub terminal developmentproject for the importation, storage, handling, and distribution oflow-carbon renewable fuels and hydrogen carriers, including greenammonia, methanol, and biofuels

The company intends to construct the development in phases, withPhase 1 accommodating 400,000 cubic meters of renewable liquid bulkstorage and supporting infrastructure

Vision Energy has engaged environmental experts and specialistNetherlands-based consultancy firms to undertake detailed studiesto support final permit applications for the development

Vision Energy (OTCQB: VENG), through its wholly owned subsidiary Evolution Terminals BV, is inthe advanced stages of planning the construction of a Green EnergyHub terminal development in the North Sea Port of Vlissingen, theNetherlands. An integrated energy company, VENG envisions adevelopment that will be capable of receiving seagoing ships,barges, and coasters, through a dedicated deep-water jetty, as wellas trains and trucks that will access storage and handlingfacilities via rail- and roadways that lead to dedicatedloading/unloading facilities.Vision Energy (OTC: VENG) (the “Company”) today issued statements regarding recent removal from the OTCQBMarket. On Dec. 6, 2022, Vision Energy was informed by the OTCMarkets Group Inc. of certain promotional material that encouragedinvestors to purchase or trade the Company’s common stock. On Jan.10, 2022, the Company was informed that, due to the ongoingpromotional campaign, it would be moved from the OTCQB Market tothe Pink Market effective Jan. 11, 2023. As detailed in the update,Vision Energy is and continues to be committed to compliance withOTC Markets’ policy on stock promotion and the OTCQB standards. Theannouncement reads, “The Company encourages those interested in theCompany to rely solely on information included in press releasesissued and distributed by the Company through approved news wire ordisclosure and news services, combined with its filings anddisclosures made with the SEC, as well as information providedthrough the OTC Markets and Vision websites.” To view the fullpress release, visit

Vision Energy Corp. (OTCQB: VENG) (“Vision Energy”) is a forward-looking energy company developing carbon reduced solutions for the commercial, industrial and transportation sectors. Vision Energy is leveraging its team’s proven track-record in site and asset procurement, accelerating development and permitting processes, plant design, and grid integration to facilitate low-carbon energy production, supply and distribution. The company is pursuing reliable offtake relationships and operating partnerships with energy industry participants and end users seeking carbon abatements across feedstock and fuels. Vision Energy is committed to providing low carbon energy solutions with maximized yield, with projects designed to exploit existing gas and power infrastructure, to integrate and facilitate import and/or distribution of reduced-carbon energy to domestic and global supply chains.

The company believes that hydrogen and liquid carriers of hydrogen are the most reliable alternatives to fossil fuels. Hydrogen is anticipated by many energy analysts to become more widely competitive as an alternative mobile energy source as early as 2030, as economies of scale drive down costs.

According to the International Energy Agency report ‘Hydrogen in North-Western Europe (2021)’, the region is well placed to lead hydrogen adoption as a clean energy source. Today, this region comprises approximately 5% of global hydrogen demand and 60% of European demand. Moreover, the region is home to the largest industrial ports in Europe, where much of this hydrogen demand is located, and presents a well-developed natural gas infrastructure connecting these ports with other industrial hubs. This gas network could be partially repurposed to facilitate hydrogen delivery from production sites to demand centers. Governments in this region also have ambitious goals for greenhouse gas emissions reduction and there is strong political interest in hydrogen as a pathway to maintaining industrial activity in the region.

Vision Energy is based in Jersey City, New Jersey.


Through wholly owned subsidiary Evolution Terminals BV, Vision Energy is pioneering a Green Energy Hub development project for the import, storage and distribution of low-carbon renewable fuels and hydrogen carriers, strategically located in the North Sea port of Vlissingen at the mouth of the Westerschelde estuary in the Netherlands. This Green Energy Hub is positioned to be the first terminal in Europe focused on green and low-carbon energy products.

Vision Energy is at an advanced stage of planning for the construction of its Green Energy Hub and is on schedule to file for the remaining construction and environmental permits by December 2022. The Green Energy Hub design is capable of receiving seagoing vessels, barges and coasters, served by a dedicated deep-water jetty as well as rail and truck loading infrastructure that will enable direct access to purpose-built storage and handling facilities for low-carbon fuels and hydrogen carriers, including ammonia, methanol and liquid organics. Phase 1 capital expense is estimated at approximately €450 million, including jetty infrastructure, and will provide for up to 400,000 cubic meters (CBM) of storage capacity with land already secured for future expansion.

Market Opportunity

In Northwestern Europe, the market for green hydrogen, or hydrogen produced by renewable energy, is growing rapidly. The current hydrogen demand projections outstrip the scheduled production for the next five to 10 years.

The company believes that all producers will face high demand. Moving beyond its initial Green Energy Hub, Vision Energy is focused on countries where governments support a regulatory standard that promotes hydrogen production and consumption. Many governments have established various incentives and financial mechanisms to accelerate and promote the use of hydrogen as a renewable energy source.

The EU, through its European Green Deal, has set an objective to become climate-neutral by 2050, implying the near total phase-out of fossil fuels in the EU energy system, and many countries are working to put in place subsidy programs for the development of green hydrogen facilities in anticipation of this goal.

Vision Energy projects its total addressable market at €10 billion by 2050.

Management Team

Andrew Hromyk is CEO of Vision Energy. He has supported and operated chemical and energy operations in the Permian Basin, central and south Texas, Arkansas, Alberta and internationally. An active investor, he has been involved with companies developing a diverse range of technologies, from enhanced and conventional hydrocarbon recovery processes to wireless infrastructure. He has participated in numerous industrial and commercial real estate developments. He also has served as a director of several private companies that became publicly traded on Nasdaq, NYSE and TSX. He studied economics at Chaminade University and the University of British Columbia.

Arron Smyth is Executive Vice President of Corporate Development at Vision Energy. He has more than 18 years of experience in financial services, investment banking, business leadership and operations in both developed and emerging markets. Since 2018, he has been Managing Director Europe for the First Finance group of companies, developing and supporting the group’s private equity investments and projects, including Evolution Terminals, the Netherlands-based developer of tank terminal and port infrastructure for the bulk storage and handling of clean and sustainable energy products.

Matthew Hidalgo is CFO of Vision Energy. He has over 15 years of experience in accounting, operations, finance, corporate restructuring and integrating acquisitions. He is a Managing Partner at Turquino Equity LLC, a private equity investment firm. Formerly, he was the controller and operations manager for the largest subsidiary of WPCS International Incorporated. Prior roles included managing accounting functions for several Australian subsidiaries. After graduating from Penn State with a bachelor’s degree in accounting, he began his career at PricewaterhouseCoopers.

Vision Energy Corp. (OTCQB: VENG), closed Monday's trading session at $2.05, up 3.0151%, on 73,251 volume with 375 trades. The average volume for the last 3 months is 57,207 and the stock's 52-week low/high is $1.04999995/$5.63000011.

Recent News

HeartBeam Inc. (NASDAQ: BEAT)

The QualityStocks Daily Newsletter would like to spotlight HeartBeam Inc. (NASDAQ: BEAT) .

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first andonly 3D-vector ECG platform for heart attack detection anytime,anywhere, was featured in a new C-level interview with Traders News Source, a leading independent equity researchand corporate access firm focused on small and mid-cap publiclytraded companies. Branislav Vajdic, PhD, CEO and founder ofHeartBeam joined Traders News Source’s Toni Loudenbeck to providean overview of HeartBeam and discuss the potential for thecompany’s innovative AIMI(TM) and AIMIGo(TM) technology. In theinterview, Dr. Vajdic shares his background and vision leading upto the company’s 12-lead standard of care technology that isdisrupting the ECG space.

To view the full press release, visit

HeartBeam Inc. (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only 3D-vector 12-lead electrocardiogram (ECG) platform for heart attack detection anytime, anywhere. The company’s proprietary ECG telehealth technology aims to redefine the way high risk cardiovascular patients are diagnosed in ambulatory and acute care settings. HeartBeam’s initial focus is on providing diagnostic data to help physicians with care management of patients with cardiovascular disease.

In August 2022, HeartBeam announced that it submitted its HeartBeam AIMI™ software for approval from the U.S. Food and Drug Administration (FDA). HeartBeam AIMI is a platform technology to improve the speed and accuracy of heart attack detection in acute care settings. The company expects FDA approval by the end of 2022, and a full commercial roll-out of HeartBeam AIMI is targeted for Q1 2023.

HeartBeam sees submission of its first product based on its platform technology as an important milestone toward commercialization, which underscores the company’s continued progress toward making the HeartBeam AIMI platform widely available to help emergency department physicians quickly and accurately identify a heart attack.

While the FDA conducts its regulatory review, HeartBeam will focus on executing key components of its commercialization plan and subscription revenue model. It will also continue to engage in discussions with strategic institutions, including academic centers, regional healthcare systems and regional community hospital systems that can utilize HeartBeam products.

The company is based in Santa Clara, California.


HeartBeam’s development portfolio includes two products:

  • HeartBeam AIMI is software that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack in acute care settings and, as noted above, has been submitted for FDA approval; and
  • HeartBeam AIMIGo™, the first and only credit card-sized 12-lead output ECG device coupled with a smartphone app and cloud-based diagnostic software system for remote heart attack detection.

HeartBeam is developing AIMIGo, a medical-grade detection and monitoring technology for use in remote heart attack detection, thereby allowing physicians to diagnose a patient’s heart attack as it occurs, even if the patient is not at a medical facility. The company’s system, once approved by the FDA, can be used by patients at home or almost anywhere and anytime to help their physicians assess whether chest pain is the result of a heart attack or another cause. While approximately 82% of chest pain ED visits are unnecessary, patients delay approximately 3 to 4 hours after symptoms begin, increasing mortality rates by 40%. The company’s goal is to shorten the time to treatment outside of the medical facility to improve patients’ well-being.

HeartBeam’s AIMIGo is a powerful, portable and easy-to-use prescription-based product. It comprises a smartphone app, a credit card-sized ECG device placed on a patient’s chest, the HeartBeam cloud platform, and a digital portal for the physician to view ECG results and direct patient action. For the first time outside of a medical setting, HeartBeam AIMIGo enables patients and their clinicians to determine if symptoms are due to a heart attack, quickly and easily, so care can be expedited, if needed.

Pending FDA clearance, AIMIGo is initially intended to be available by prescription, and is reimbursable under existing remote patient monitoring codes (RPM codes). This provides a new revenue stream to physicians who before did not have a way to monitor these high-risk patients. The RPM codes provide a monthly reoccurring revenue stream to the company, as well. On average, at current reimbursement rates, the practice will receive $1,300+ per year per patient they monitor, and the company will receive $600 per year per patient from this RPM reimbursement.

Market Overview

Adoption rates of telehealth services increased dramatically in recent years, with the COVID-19 pandemic serving as a major driver of growth. Among the areas seeing the greatest expansion are cardiology, radiology, behavioral health and online consultation.

Encouraging this growth, governments are actively developing new policies and reimbursement guidelines to promote the use of digital health platforms. The U.S. Centers for Medicare & Medicaid Services (CMS), for example, has recently expanded reimbursement for telehealth services. U.S. market growth is also being driven by the rising prevalence of chronic conditions and the growing geriatric population.

Remote heart attack detection is a previously unsolved problem with a massive and underserved market that is several times larger than the $2 billion total addressable market (TAM) in the U.S. for ECG cardiac arrhythmia monitoring.

Approximately 8 million Americans have suffered at least one heart attack, and a total of 18 million have been diagnosed with coronary artery disease (CAD). Based on these figures, HeartBeam projects a total addressable U.S. market TAM valued at $10 billion annually for its AIMIGo solution for remote heart attack monitoring of CAD.

Management Team

Branislav Vajdic, Ph.D., Chief Executive Officer and Founder of HeartBeam, Inc, combines over 30 years of experience in technology development and senior management positions. Dr. Vajdic has been deeply involved with the development of HeartBeam’s technology to fit his vision for the company. Prior to HeartBeam, from 2007 to 2010, Dr. Vajdic was CEO and Founder of NewCardio, a publicly traded company in the cardiovascular devices space. From 1984 to 2007, Dr. Vajdic was at Intel, where he held various senior management position. At Intel, Dr. Vajdic was the designer of first Flash memory and two key inventions that enabled Flash as a product and led engineering groups responsible for Pentium 1 through Pentium 4 designs. Dr. Vajdic was awarded two Intel Achievement Awards, the highest level of award for outstanding contributions to Intel. Dr. Vajdic is author of numerous patents and publications in the fields of cardiovascular devices, as well as chip design. Dr. Vajdic holds a Ph.D. in Electrical Engineering from the University of Minnesota.

Jon Hunt, Ph.D., has over 35 years’ experience in the medical/medical device industry with extensive domestic and international experience in general management, clinical/regulatory, sales and marketing. He also has diverse experience in Fortune 500 companies, as well as start-up environments. Dr. Hunt was the Vice President of Clinical Science and Technology, Medical Device Innovation Consortium, from July 2019 to July 2021, and Vice President of Clinical and Regulatory Affairs, Cryterion Medical from January 2018 to June 2019 (acquired by Boston Scientific Corporation in July 2018 for $202M). Dr. Hunt was the Founding President and CEO of Bardy Diagnostics, Inc. from October 2013 to November 2017 (acquired by Hill-Rom Holdings, Inc.). Prior to joining Bardy Diagnostics, Dr. Hunt spent the previous 11 years as the Vice President of Clinical & Regulatory Affairs with Cameron Health, Inc. (acquired by Boston Scientific Corporation). Dr. Hunt spent the previous 10 years with Cardiac Pacemakers, Inc., St. Jude Medical and Cardiac Pathways Corporation. Dr. Hunt began his career with Cardiac Pacemakers, Inc. (now Boston Scientific Corporation) as the Director of Clinical Programs. He subsequently held positions at St. Jude Medical in Clinical Affairs and as the Business Unit Director for the Cardiac Rhythm Management division for Europe, the Middle East and Africa. At Cardiac Pathways Corporation, Dr. Hunt held various executive positions as Vice President of International Sales and Marketing and Vice President of Worldwide Sales and Marketing (acquired by Boston Scientific Corporation). Dr. Hunt received his Ph.D. in Motor Control from The Pennsylvania State University, his Master’s from California State University, Long Beach and his undergraduate degree from Keele University in the United Kingdom.

Rick Brounstein, HeartBeam’s Chief Financial Officer, combines over 30 years of experience in health technology senior management. Since 2017, Mr. Brounstein has been and is currently a partner of Hardesty, LLC, a financial services firm, and Mr. Brounstein is currently a managing director of CTRLCFO, LLC, a firm Mr. Brounstein founded in 2016 to support funded start-ups in life science and technology. From 2008 to 2011, Mr. Brounstein was Chief Financial Officer of NewCardio, Inc., a microcap public company in the cardiology space, and, over his career, he has been with nine other companies in life science or technology, holding positions including Chief Financial Officer, Chief Operating Officer, Treasurer and Accounting Manager. From June 2001 through November 2007, Mr. Brounstein held several positions at Calypte Biomedical Corporation, a publicly traded medical device company, including Chief Financial Officer and Executive Vice President. In January 2007, Mr. Brounstein was appointed as the National Member Representative for the 2007 COSO Monitoring Project, which published new guidelines for monitoring internal financial controls in February 2009; Mr. Brounstein subsequently was a member of the FEI task force that issued the updated COSO Internal Control Framework in 2013. In March 2005, Mr. Brounstein was appointed to the SEC Advisory Committee on Smaller Public Companies. Mr. Brounstein earned his Certified Public Accountant (CPA) certification while working at Arthur Andersen LLP, formerly a public accounting firm. Mr. Brounstein holds a B.A. in accounting and an M.B.A. in finance, both from Michigan State University.

Ken Persen, HeartBeam’s Chief Technology Officer, combines over 28 years of experience in the medical device and digital health industries in engineering and senior management positions. Mr. Persen has been involved in several companies in Cardiac Rhythm Management, holding positions including Chief Executive Officer, Chief Technology Officer, Executive Vice President and Director of Engineering. Since 2016 and prior to joining HeartBeam, Mr. Persen was the Chief Technology Officer at LIVMOR, Inc., a digital health company. In addition, from 2016 through November 2021, he was also Chief Executive Officer of LIVMOR. Prior roles included Director of Engineering at Cameron Health (acquired by Boston Scientific), a late-stage medical device start up, and engineering and management positions at Guidant Corp. (acquired by Boston Scientific), a large medical device manufacturer. He has an undergraduate degree from University of Minnesota, Duluth, with a BA in Computer Science.

HeartBeam Inc. (NASDAQ: BEAT), closed Thursday's trading session at $4.22, up 5.2369%, on 87,174 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $26.10/$.

Recent News

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

Lexaria Bioscience Corp. (NASDAQ: LEXX) in 2022 achieved crucial milestones centered around its patentedDehydraTECH(TM) drug delivery technology. “For Lexaria, the endgoal does not only lie in uncovering DehydraTECH’s ability toimprove the bioavailability of various APIs. Instead, the companyis keen on establishing whether DehydraTECH can be applied broadlywithin the pharmaceutical industry. And calendar 2022 has broughtLexaria closer to realizing this goal, with the company initiatinga slew of research programs, many of which it has alreadycompleted. Moreover, its intellectual property (‘IP’) portfolioreceived additional patent protection in different jurisdictionsaround the world. Lexaria also entered into multiple manufacturingand/or licensing agreements with global partners,” a recent articlereads. “The company’s 2022 research programs included: a) an animalstudy evaluating DehydraTECH-processed sildenafil, aphosphodiesterase (‘PDE5’) inhibitor used in the management oferectile dysfunction; b) a 16-person hypertension study,HYPER-H21-3, and a 66-person hypertension study, HYPER-H21-4, bothevaluating DehydraTECH-CBD as a potential treatment for high bloodpressure; c) a three-part animal study assessing the effectivenessof DehydraTECH-CBD in reducing seizure activity compared to theFDA-approved seizure medication Epidiolex; d) separateinvestigations on the potential therapeutic use of DehydraTECH-CBDin both diabetes (‘DIAB-A22-1’) and dementia (‘DEM-A22-1’); and e)a human oral nicotine study, NIC-H22-1, designed to compare theperformance of Lexaria’s DehydraTECH-nicotine pouch to On!’s (apouch brand manufactured by Altria) and Zyn’s (the world’s leadingnicotine pouch product manufactured by Swedish Match).”

To view the full article, visit

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Thursday's trading session at $2.7375, up 3.3058%, on 5,438 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.80/$4.94.

Recent News

CISO Global, Inc. (NASDAQ: CISO)

The QualityStocks Daily Newsletter would like to spotlight CISO Global, Inc. (NASDAQ: CISO).

Cerberus believes successful cybersecurity must be woven into anorganization’s fabric, transforming its culture

While cybersecurity has become a well-known topic, surprisingly fewcompanies are doing anything about it

Every 11 seconds, someone is targeted or hacked, and the weakestlink inside a company is people who aren’t prepared, says CISO CEO

The idea that “cybersecurity is a culture, not a product” has neverbeen more relevant or profound, says podcast host Ted Jenkin, whochatted with Cerberus Cyber Sentinel (NASDAQ: CISO) CEO David Jemmett during a recent episode of “The Shrimp Tank” ( Cerberus has trademarked that phrase and operates on theprinciple that successful cybersecurity is more than amassing alist of vendors and varied technologies; it must be woven into thefabric of an organization, encompassing and transforming thatorganization’s culture.

CISO Global, Inc. (NASDAQ: CISO) is an industry leader in cybersecurity and compliance services. The company leverages an integrated approach to reduce noise and bridge common silos that often limit the effectiveness of cybersecurity programs. Pulling disparate technologies, teams, and vendors together, CISO helps its clients enjoy a simpler and more successful journey to cyber resilience. Since 2019, CISO Global has worked to rapidly expand by acquiring world-class cybersecurity and compliance businesses with top-tier talent who utilize the latest technology to create innovative protection solutions.

The CISO Global workforce is comprised of cybersecurity experts spanning not only global geographies, but also specialties, industries, regulatory frameworks and focus areas. Its team includes audit and compliance specialists, certified forensics experts, ethical hackers, IEEE® certified biometric professionals, security engineers, around-the-clock analysts, and more – all backed by the most respected credentials in the industry. On an ongoing basis, the company works to identify cyber talent that is culturally aligned and that offers operating leverage through both existing customer revenue and relationships.

CISO Global has invested in enterprise solutions and executive talent to integrate its different organizations into an ecosystem that works together to provide complete cybersecurity through cross-pollination of solutions that begin at the network level and extend through technologies, people, policy, and practices. This ecosystem is intended to foster additional growth opportunities and drive overall recurring revenue. Once engaged, the company strives to become trusted advisors for customers’ cybersecurity and compliance demands by providing tailored security solutions based upon their organizational needs.

While cyber resilience requires cycles of continuous improvement, it is a journey that few in the current business and security climate seem to understand. With its deep bench of seasoned experts, CISO Global works to simplify that journey for its growing customer base, straightening out the curves and speeding up the process to resilience along the way.

Cybersecurity is a Culture, Not a Product

Integrating compliance and security, including principles of security by design, CISO Global helps its clients create an organization-wide culture of cybersecurity. Its offerings include audit and compliance, security operations center services, security engineering, virtual Chief Information Security Officer services, incident response, certified forensics, technical assessments and cybersecurity training.

In contrast to the majority of cybersecurity firms that specialize in a specific technology or service, CISO Global seeks to differentiate itself by remaining technology agnostic, focusing on accumulating highly sought-after subject matter experts. CISO Global believes that bringing together a world-class team of technological experts with multi-faceted proficiency in the critical aspects of cybersecurity is key to providing technology agnostic solutions to its clients in a business ecosystem that suffers from a chronic lack of highly skilled professionals.

CISO Global’s goal is to create a culture of security and to help quantify, define and capture a return on investment from information technology and cybersecurity spending. Its end-to-end, holistic process covers every aspect of clients’ cybersecurity and compliance requirements in an effort to promote greater efficiency and strengthen awareness about the integral role of internal team members in the cybersecurity culture of an organization.

As a result of this strategy, CISO Global customers receive an efficient engagement from a single partner that covers a wide range of their needs – addressing challenges more thoroughly and resolving problems more rapidly when compared to working with a host of vendors.

Market Outlook

According to an analysis by the firm Research and Markets, the global managed security services market was valued at $22.45 billion in 2020 and is projected to reach $77.01 billion by 2030, growing at a CAGR of 12.8% through the forecast period.

An expected increase in cybercrime, cost effectiveness of provided solutions and stringent mandatory government regulations aimed at protecting corporate data will drive the global managed security services market for the foreseeable future.

In addition, the documented and growing use of mobile devices in the workplace and the rise in captured and stored digital data serve to fuel market growth. Moreover, growing awareness about the critical nature of data security, the growing importance of e-business and demand for customized services is expected to offer ample opportunities for expansion of the market during the forecast period.

Management Team

David Jemmett is CEO and founder of CISO Global. He has more than 35 years of executive management and technology experience with telecommunications, managed services, and cybersecurity consulting services. He previously held positions as CEO of GenResults, a leading provider of security consulting services and technology solutions, and as CTO and founder at ClearData Networks, a HIPAA-compliant HealthDATA cloud hosting platform.

Dave Bennett is COO at CISO Global. Since 2015, he has served on the President’s STEM Advisory Board of Grand Canyon University. Before joining CISO Global, he served as Chief Product Officer at Experian Health and as Senior Vice President, Product for Gainwell Technologies. He has also held positions as Vice President and Worldwide Head of Build, Healthcare and Life Sciences at DXC Technology, and as EVP, Product and Strategy at Orion Health.

Ashley Devoto is President and Chief Information Security Officer at CISO Global. Over the past 17 years, Devoto has worked with the cybersecurity elite to design, build, and operate world-class cybersecurity programs for large, diverse organizations in both government and commercial enterprises. Prior to joining CISO, Devoto served as CISO for Booz Allen Hamilton, as business information security officer (BISO) at Bank of America, and as a cyberspace operations officer in the United States Air Force.

Deb Smith is CFO at CISO Global. Prior to assuming that position, she was the company’s EVP, Finance and Accounting. She has also served as SVP, Global Accounting at International Cruise and Excursions Inc., and as Chief Accounting Officer for BeyondTrust, an information security software company. She has also held the positions of Corporate Controller at Aspect Software and Assistant Controller at JDA Software.

CISO Global, Inc. (NASDAQ: CISO), closed Monday's trading session at $2.05, up 3.0151%, on 73,251 volume with 375 trades. The average volume for the last 3 months is 57,207 and the stock's 52-week low/high is $1.04999995/$5.63000011.

Recent News

Cepton Inc. (NASDAQ: CPTN)

The QualityStocks Daily Newsletter would like to spotlight Cepton Inc. (NASDAQ: CPTN).

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance lidarsolutions, reported that its stockholders approved the company’sproposal to issue 100,000 shares of Series A Convertible PreferredStock to Koito Manufacturing Co. Ltd. The issuance, which would befor $100 million, is based on the terms of an investment agreementbetween the two companies that was signed on Oct. 27, 2022.According to the announcement, the investment should close on Jan.19, 2023. Shareholders voted on the proposal during Cepton’s recentspecial meeting of shareholders, which was held on Jan. 11, 2023.

To view the full press release, visit

Cepton Inc. (NASDAQ: CPTN) is a provider of state-of-the-art, intelligent, lidar-based solutions serving a range of markets, including automotive (ADAS/AV), smart cities, smart spaces and smart industrial applications. General Motors (NYSE:GM) has granted a series production award for Cepton’s lidar, the biggest such award to date in the automotive space. Cepton’s is the lidar component of GM’s Ultra Cruise autonomous driving platform. By leveraging its patented Micro Motion Technology (MMT®) lidar platform, the company develops reliable, scalable and cost-effective solutions that deliver long-range, high-resolution 3D perception for smart applications.

Cepton was established in 2016 by co-founders Dr. Jun Pei and Dr. Mark McCord. The company is headquartered in San Jose, California, and serves a fast-growing customer base through an international presence spanning North America, Germany, Japan, India and China.

Micro Motion Technology (MMT®)

Cepton was built from the ground up to meet key lidar industry challenges for mass market adoption. This company’s portfolio of proprietary technology is uniquely aimed at facilitating this industry growth through a combination of performance, reliability, affordability and design integration.

Key among its innovations is MMT®, a mirrorless, frictionless, rotation-free 3D imaging platform designed specifically for lidars. Its benefits for OEMs and system integrators include:

  • Reliability – The durable design uses common, easily attainable materials.
  • Versatility – The platform is capable of achieving near- to ultra-long range with a wide field of view.
  • Efficiency – MMT® features a compact form factor, low power usage and inexpensive components.
  • Scalability – Its simple design means that scale-up to high manufacturing volumes is easily attainable.

Because of their compact form factor, Cepton lidars are embeddable and ideally suited for advanced driver-assistance system (ADAS) integration, whether behind windshield, in headlamp or in fascia.

Agreement with KOITO

KOITO Manufacturing Co. Ltd., the world’s premier Tier 1 auto lighting supplier, originally started an evaluation of Cepton’s MMT® based lidars in 2018. In 2020, KOITO made an investment in Cepton aimed at accelerating the company’s development and enabling KOITO’s industrialization of high-performance and high reliability lidar sensors for ADAS and autonomous vehicle (AV) applications.

Through this collaboration, Cepton was able to secure the largest ADAS lidar series production award[1] with General Motors as a sole source in the automotive space. The award covers GM vehicles for the initial period of 2023-2027.

On August 5, 2021, the two companies deepened their relationship when KOITO committed to invest a further $50 million in Cepton’s business through its participation in a Private Investment in Public Equity (PIPE) offering of shares of common stock of Growth Capital Acquisition Corp. in connection with Cepton’s recent merger.

Collaboration with GM

On July 13, 2021, Cepton announced that it had secured an ADAS lidar series production award from a leading, Detroit-based global automotive OEM – the biggest lidar production award by any OEM to any lidar company. It was later clarified that the OEM was General Motors, and Cepton’s lidar is part of GM’s ADAS Ultra Cruise system.

GM is “expected to deploy Cepton lidars in its next generation of advanced driver assistance systems (ADAS) across multiple vehicle classes and models – not just luxury cars.” As such, the agreement marks the potential for “an industry-first, mass-market adoption of lidar technology for automotive ADAS, with an anticipated deployment in consumer vehicles starting in 2023.”

On July 28, 2021, Ford Motor Company (NYSE: F) distributed an article on Medium noting, “Ford has been engaged with Cepton almost since their inception in 2016, both for R&D collaboration and small-scale deployments. Cepton LiDAR are deployed in some of [Ford’s] smart city projects. Based on Ford’s guidance, Cepton delivered a custom version of their LiDAR to enable R&D on advanced ADAS features.”

Market Outlook

Driven by increasing development and adoption in automobile safety applications, environmental mapping and 3D-modeling, the global lidar market is forecast to experience considerable growth over the coming years. A research report published by MarketsAndMarkets suggests that the sector will grow to an estimated $3.4 billion by 2026, achieving a CAGR of 21.6% over the next five years.

The report further highlights increasing investments in lidar startups by automotive giants as a driver of growth opportunities in the sector, particularly in North America.

In 2020, ground-based lidar accounted for the lion’s share of the overall lidar market, and this trend is expected to continue as the automotive sector continues to rapidly advance adoption across the full spectrum of vehicle classes. One factor not to be underestimated is the high barrier of entry and the exceptionally long time required for automotive OEMs to vet and award a production win to a lidar company. It is a commonly held view that the over 50 lidar companies will inevitably coalesce into a handful serving all OEMs.

Cepton, having a head start through its established partnership with leading global OEM GM, is uniquely positioned to capitalize on this market growth in the years to come.

Management Team

Cepton’s founder-led team is made up of lidar industry pioneers with decades of collective experience across advanced lidar and imaging technologies.

Jun Pei, Ph.D., is the company’s CEO and Co-Founder. He is a technology specialist with a focus in optics and electronics. Prior to founding Cepton, Dr. Pei founded AEP Technology, a firm focused on developing advanced 3D optical instruments. He received his Ph.D. in electrical engineering from Stanford University.

Mark McCord, Ph.D., is Cepton’s CTO and Co-Founder. Prior to founding Cepton, he led advanced development at KLA-Tencor. Dr. McCord also formerly served as an associate professor at Stanford University, where he earned his Ph.D. in electrical engineering.

Winston Fu, Ph.D., is the company’s CFO. Dr. Fu is the founder of Silicon Valley venture capital firm LDV Partners. Prior to joining Cepton, he served as CFO and Chairman of Active-Semi before its acquisition. Dr. Fu has also helped to build many technology companies as an entrepreneur and/or board member. He received his Ph.D. in applied physics from Stanford University, as well as an MBA from the Kellogg School of Management at Northwestern University.

[1] Largest known ADAS lidar series production award based on number of vehicle models awarded

Cepton Inc. (NASDAQ: CPTN), closed Thursday's trading session at $1.22, up 4.2735%, on 219,838 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.01/$80.16.

Recent News

Flora Growth Corp. (NASDAQ: FLGC)

The QualityStocks Daily Newsletter would like to spotlight Flora Growth Corp. (NASDAQ: FLGC).

To become self-sufficient in the production of medical marijuana, Italy is cultivating plants with covert nutrients inmilitary-grade sterile environments. According to DefenseNews, Italy’s army aims to produce more than 1,500 pounds ofhigh-quality marijuana or about 50% of the estimated 3,300-pluspounds that the nation needs each year to meet the needs of thosewho use it to manage their chronic pain from diseases such asParkinson’s disease or cancer. Cannabis is imported into Italy fromCanada, Holland, Germany and Denmark. With the opening of themilitary facility in Florence, however, the country hopes toproduce a premium product with an unrivaled dosage at a costcomparable to imported cannabis. The Florence operation, whichbegan operations in 2014, achieved 110.2 pounds in 2020 andexpanded to 661.4 pounds in 2022. This expansion was made possibleby increasing the number of growing rooms from two in 2016 to 10most recently. To achieve the 1,500 pounds of cannabis requiredthis year, lab technicians are working on improving watering,lighting, and ventilation. They also use a mix of top-secretnutrients created internally. As nations such as Italy try toestablish their own cannabis production systems, they are likely tokeep depending on international suppliers such as Flora Growth Corp. (NASDAQ: FLGC) while waiting for their local capacity to grow to the requiredlevel.

Flora Growth Corp. (NASDAQ: FLGC) is an internationally focused cannabis brand builder that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions, including cosmetics, hemp textiles, and food and beverage. Flora Growth operates one of the largest outdoor cultivation facilities in the world with an aim of marketing a higher-quality premium product at below-market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, the company creates premium products that help consumers restore and thrive.

Flora Growth completed the first traditional cannabis IPO on Nasdaq in May 2021. Although currently headquartered in Toronto, Ontario, with plans to relocate its head office to Miami, Florida, the company’s base of operations is in Colombia, where it has built an extensive distribution network that includes Colombia’s largest distributors.

Currently, Flora Growth is organically growing market share for its existing brand portfolio (pharmaceuticals, textiles, cosmetics, and food & beverage) while seeking revenue-generating acquisitions that offer an accretive distribution network to amplify revenue growth.

Existing Brand & Product Portfolio

Flora Growth’s portfolio spans a number of verticals – each with a thoughtful brand designed to resonate with its intended end consumer. In line with the company’s mission, each brand prioritizes natural ingredients and value-chain sustainability.

Flora Lab S.A.S

Flora Lab is the company’s GMP certified manufacturing and R&D center focused on producing pharmaceuticals, cosmetics, and nutraceuticals for domestic and international markets. Its offerings include product lines that are private label, white-label, and custom formulas.

Through Flora Lab, Flora Growth has relationships with 1,500+ distribution channels, manufactures 63+ OTC products registered with INVIMA (Colombia National Food and Drug Surveillance Institute), and holds multiple GMP certifications enabling international export in an effort to leverage Flora Lab’s capacity to produce a wide range of CBD-infused products.

Flora Beauty

Flora Beauty is the company’s CBD beauty and cosmetics division founded by fashion and beauty industry icon Paulina Vega. Its current offerings include two CBD skincare brands targeting the U.S. and Latin American markets – MIND NATURALS and AWE. These lines exemplify Flora Growth’s socially conscious approach to business.

Currently, Flora Beauty products are offered globally through e-commerce, as well as through Falabella’s 111 retail locations across Latin America. The company is in negotiations with major department stores to launch the line in the U.S. and is also exploring opportunities in the U.K. and other European markets.

KASA Wholefoods

KASA Wholefoods is a Colombian manufacturer of food and beverages leveraging responsibly sourced exotic fruits from the Amazon. KASA has a $10 million+ distribution agreement with Tropi, Colombia’s largest food distributor, which has 130,000+ distribution points across the country.

Mambe, KASA’s leading brand, is already offered through over 980 distribution points across Colombia. Flora Growth expects this network to grow to over 1,200 distribution points in 2021, including one of Colombia’s largest coffee chains, Tostao Café & Pan.

Hemp Textiles & Co.

Through its Hemp Textiles division, Flora Growth intends to utilize its large land package and cultivation infrastructure to capture market share in the rapidly growing hemp industrials segment.

The company’s first brand through this division, Stardog Loungewear, offers a line of comfortable loungewear made from natural, organic materials. Stardog has been distributing globally through e-commerce and brick and mortar channels in Bogota since fall 2020, and the company intends to open U.S. brick and mortar locations in 2021.

Accretive M&A

Flora Growth is targeting transactions to complete the supply chain via key infrastructure to enhance its global distribution with the aim to compete on low-cost, high-quality inputs paired with premium brands that create business lines with robust margins.

To date, Flora has announced two major transactions.

Koch & Gsell (Acquisition)

  • Amplify CPG portfolio’s revenue growth through leading brand, Heimat, currently with TTM revenues of $7.6 million.
  • Leverage Koch &Gsell’s distribution network of 2,500+ stores to introduce Flora to the Swiss, European and Asian markets.
  • Bring patented hemp cigarette manufacturing technology into new markets utilizing Flora’s high-quality cannabis.

Hoshi International (Investment)

  • Equity Investment of €2 million into Hoshi to establish Flora as a preferred supplier to two EU processing facilities.
  • Opens gateway for Flora Growth’s cannabis through international distribution agreements in the EU and U.K.
  • Hoshi’s experienced team and increased access to the EU cannabis market to serve as a catalyst for revenue growth.


Key to Flora Growth’s expansion efforts is its cultivation strategy. The company’s Cosechemos farm, located in Bucaramanga, Colombia, is currently licensed to cultivate 247 acres of cannabis. Through three successful pilot crop plantings, the location has demonstrated a production cost of just $0.06/gram. For comparison, the average cost of North American cannabis (based on 2019 figures from Aphria, Tilray, Sundial, and Aurora) equates to roughly $1.89/gram.
Flora Growth is uniquely positioned to capitalize on Colombia’s favorable growing conditions, low-cost infrastructure, and affordable local workforce as it looks to ramp up its cultivation efforts moving forward.

Leadership Team

Bernard Wilson is the Chairman of Flora Growth. A senior financial professional, Dr. Wilson is the former Vice-Chairman of PricewaterhouseCoopers LLP and is the Chairman of the Founders Board of the Institute of Corporate Directors. He has also served as Chairman of the Canadian Chamber of Commerce; Chairman of the International Chamber of Commerce – Canada; and Member of the Canada/U.S. Trade Committee. Dr. Wilson draws on this experience to ensure Flora Growth adheres to effective corporate governance practices.

Luis Merchan is the company’s President and CEO. He is a proven executive with over a decade of experience in enterprise sales management, corporate strategy, merchandising and expense management, and customer experience. Mr. Merchan previously served as Macy’s Inc.’s Vice President of Workforce Strategy and Operations, where he managed the enterprise’s multi-billion-dollar P&L expense line for the entire 540 store portfolio. Throughout his tenure at Macy’s, he led various sales and marketing initiatives, including the B2B corporate sales team that was responsible for $160 million in annual revenue. Mr. Merchan obtained his Bachelor of Industrial Engineering from Pontifical Xaverian University in Bogota, Colombia, and his MBA from McNeese State University. He also holds a Graduate Certificate in Marketing Management from Harvard.

Juan Manuel Galan is a Strategic Advisor to the Flora Growth management team. Mr. Galan currently serves as a senior consultant to The World Bank. He is a politician and former senator of Colombia, serving three terms from 2006 to 2018 as a member of the Colombian Liberal Party. He is also a former professor at the University of Rosario and holds more than 20 years of journalistic, academic, governmental and parliamentary experience. During his time as a senator, Mr. Galan was a key leader, with 29 bills and 27 debates on political control, and 17 laws to his name. The most relevant of those laws was authoring the medical cannabis law that resulted in the legalization of medical cannabis in Colombia.

Stan Bharti is a Director of Flora Growth. Mr. Bharti currently serves as Executive Chairman of Forbes & Manhattan. He has more than 30 years of professional experience in business, finance, markets, operations and more, with a focus on the resource and technology sectors. To date, Mr. Bharti has amassed over $3 billion worth of investment capital for the companies with which he has worked and their shareholders. He is a Professional Mining Engineer and holds a master’s degree in engineering from Moscow, Russia, and University of London, England.

Javier Franco is the company’s VP of Agriculture. Mr. Franco is a master horticulturist with more than 25 years of experience in the design, implementation, and management of cultivation and propagation facilities of more than 30 species of cut flowers in Latin America. He completed his agricultural studies at Zamorano University in Honduras and later at an International Exchange Program at Ohio State University. Mr. Franco has directed technical, commercial, and research groups in the cut flower, fruit and vegetable markets in Latin America and has participated in the commercial development of new technologies applied in agribusiness. He has also led the agri-management of organic crops and certifications of Good Agricultural Practices.

Flora Growth Corp. (FLGC), closed Thursday's trading session at $0.2, up 2.5641%, on 3,133,492 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.1913/$2.38.

Recent News

Coyuchi Inc.

The QualityStocks Daily Newsletter would like to spotlight Coyuchi Inc.

Coyuchi is setting the gold standard in sustainable luxury home goods,offering organic bedding, sheets, towels, apparel, and more for theenvironmentally conscious home. “For 30 years, Coyuchi has exploredorganic farming and sustainable textiles, and guarantees thehighest environmental and ethical standards through its acquisitionof certifications, including the Global Organic Textile Standard(‘GOTS’), Fair Trade Certified, and MADE SAFE(R). Backed by aseasoned leadership team, a robust e-commerce shopping experience,and a healthy customer base driving the fast-growing organic luxurymarket, Coyuchi is positioned to propel its new growth phase as theworld awakens to sustainability at scale,” a recent article reads.“Coyuchi is built upon four foundational pillars — protecting theenvironment, innovating circular design, living sustainably, andenriching the community. Coyuchi’s product assortment consists ofconsciously designed products spread across 1400 SKUs.”

To view the full article, visit

Coyuchi is the gold standard in sustainable luxury home goods. The company offers sustainably produced luxury organic bedding, sheets, towels, apparel, and other home goods for the environmentally conscious home. With a timeless, coastal-inspired aesthetic, Coyuchi uses only 100% organic cotton materials to manufacture all of its textiles.

The Company was built upon four foundational pillars: protect the planet, innovate circular design, live sustainably, and enrich the community. These guiding principles have proven an effective market strategy. In 2021, Coyuchi earned $33.3 million in net sales, amounting to 26% YoY growth (the industry average is only 5%). It also experienced 2x customer growth to 200,000 active customers, averaging a 35% customer repeat purchase rate.

With a seasoned leadership team, a robust e-commerce shopping experience, and a healthy customer base that drives the fast-growing organic luxury market, Coyuchi is prepared to propel a new phase of growth as the rest of the world finally awakens to sustainability at scale.

A Lucrative Market Ripe for the Taking

The global market for organic bedding, which was estimated at $814.3 million in 2020, is projected to reach $1.1 billion by 2027, growing at a CAGR of 4.9% over that period, according to Research and Markets. More specifically, the domestic organic bedding market is estimated at $240.1 million in 2020, according to Statista. Overall, the U.S. market for home textiles is currently valued at $25 billion annually, and, with a forecast annual growth rate of 5%, it is expected to reach $30 billion by the end of 2025.

Grand View Research reported in 2020 that shifting consumer preference toward high-end lifestyle products is a key factor driving the growth of the organic bedding market. Seventy-four percent of consumers are willing to pay more for sustainable products – a consumer preference that has steadily increased over the last few decades. Millennials especially favor ethical consumption over price when purchasing goods and services, with 83% of millennials reporting that they want the brands they purchase from to align with their beliefs and values ( With a majority millennial customer base, Coyuchi is poised to capitalize on this trend.

Industry Defining Sustainability Practices

For 30 years, Coyuchi has explored organic farming and sustainable textiles and guarantees the highest environmental and ethical standards through a number of certifications such as The Global Organic Textile Standard (GOTS), Fair Trade Certified, and MADE SAFE®.

Coyuchi continues to push the organic textile market forward through its circularity initiatives and by supporting cross-industry sustainability advocates. Coyuchi’s mission to bring beauty and comfort to every home without sacrificing the health of our planet has resulted in a number of important sustainability checks and balances.

  • A Circular Business Model: Coyuchi has cultivated a holistic 360-degree approach that contributes to the fight against climate change with its take back and recycling program, 2nd Home™. In 2017, it became the first luxury home brand to implement such an initiative, and, since then, the company has eliminated 68,758 lbs. of toxic chemicals from homes and renewed 6,000 lbs. of textiles.
  • The Coyuchi Climate Council: In early 2022, Coyuchi introduced a cross-disciplinary council with a goal of Net Zero Emissions by 2025 and Net Positive Emissions by 2030. The Coyuchi Climate Council brings together influential minds across fashion, regenerative farming, and sustainability who have the knowledge and experience necessary to achieve climate change.
  • C4: The California Cotton & Climate Coalition: Most recently, Coyuchi announced it is a founding member of C4, which includes innovative, sustainable fashion, apparel, and personal care brands like MATE the Label, Outerknown, Reformation, and Trace. Working together pre-competitively, C4 creates a structure for investing in regionally grown, Climate Beneficial™ cotton and directly supports the livelihoods of the farmers that grew it. Coyuchi is the only home industry brand currently involved in the project.

Omnichannel Business Model

Coyuchi differentiates itself through an omnichannel and circular business model, both of which have proven a clear draw for customers. It was an early adopter of an e-commerce sales and marketing approach (over 80% of its sales are directly through, creating a distinct advantage over incumbents and start-up newcomers in the luxury space. This has resulted in a high lifetime value customer, luxury retail partners such as Nordstrom, and a flagship store in Marin County.

Coyuchi’s Organic Textile Products

Coyuchi’s product assortment consists of consciously designed bedding, bath, apparel, and lifestyle products spread across about 1,400 SKUs. The company believes that its product assortment, produced from 100% organic cotton with Global Organic Textile Standard (GOTS) certification, provides it with a significant competitive advantage. GOTS is the world’s leading textile processing standard for organic fibers, ensuring the organic status of textiles after harvesting raw materials through environmentally and socially responsible manufacturing all the way to labeling, a major environmental and social benefit over conventional cotton product production.

Coyuchi’s focused product assortment consists of four core categories:

  • Bedding – A full suite of sustainable, organic, and high-quality sheets, duvet covers, blankets, and throws.
  • Bath – A luxurious line of towels, bath rugs, and mats.
  • Apparel – Premium apparel for men and women, including robes, sweaters, pants, and pajamas.
  • Lifestyle – The lifestyle category offers 135 SKUs, from organic napkins to crossbody totes.

Management Team

Eileen Mockus is President and CEO at Coyuchi. She has more than 25 years of experience in retail, having held positions in textile development at Patagonia, Pottery Barn Teen, and The North Face. She earned a bachelor’s degree in textiles and clothing from UC Davis and an MSBA from San Francisco State University.
Sejal Solanki is Chief Marketing Officer at Coyuchi. She previously served as the company’s Vice President of E-Commerce. Before joining Coyuchi, she worked at teen clothing giant Charlotte Russe. She oversees the company’s digital marketing, site experience, brand marketing, and e-commerce strategy.

Marcus Chung is Coyuchi’s COO, overseeing supply chain, sourcing strategy, sustainability, and IT. He previously held positions at notable direct-to-consumer brands Third Love and Stitch Fix, as well as national retailer The Children’s Place. He holds a bachelor’s degree from Wesleyan University and an MBA from UC Berkeley’s Haas School of Business.

Margot Lyons is Director of Sustainability and Sourcing at Coyuchi, where she works with strategic partners to ensure all the company’s product sustainability standards are met. She received a master’s degree in textiles and clothing from UC Davis.

Use of Proceeds

This round of funding will be used to increase Coyuchi’s enterprise value through expanded marketing, product category expansion, continued physical presence, and B2B strategic partnerships with wholesalers, and online marketplaces.

Recent News


REZYFi, Inc.

The QualityStocks Daily Newsletter would like to spotlight REZYFi, Inc.

A recent report by Montana’s Department of Revenue (DOR) providedan analysis of the state’s first year of legalized recreational cannabis sales. According to the data, marijuana sales for both personal and medical purposes totaled$303,563,878 in 2022. Adult-use marijuana generated $202,947,326 ofthe total, while medical cannabis generated $93,616,552. Thedepartment reported total sales of $25,653,687 in December, whichremains at par with the averages of each month all year long.Although the overall figures haven’t changed a lot, adult-usetransactions have increased their market share from 58% at thebeginning of the year to nearly 77%. According to Pepper Petersen,president of the Montana Cannabis Guild and a key player in thefight for recreational cannabis legalization, the total anticipatedsales for last year were between $260 million and $280 million,thus the actual amount was significantly higher. Petersen statedthat the numbers represented approximately 40 tons of marijuana inthe entire state, all of which was grown and sold in Montana.Furthermore, Petersen estimates that the industry currentlysupports approximately 5,000 employment opportunities in the state.The success of newly launched cannabis markets such as the one inMontana shows that if industry players can access funding fromvarious sources, including REZYFi Inc. and traditional banks, rapid growth can occur and residents willhave a lot more products to choose from at competitive prices.

REZYFi, Inc. is a cannabis mortgage bank servicing the needs of both traditional and non-traditional consumers and businesses. Its target markets include licensed and permitted cannabis companies, owners of real estate who lease to cannabis companies, and companies and individual homeowners seeking a variety of real estate-related first and additional mortgage-based financing and project-specific financings, such as solar installations and real estate development projects.

Headquartered in Miami, Florida, REZYFi operates through two wholly owned subsidiaries – REZYFi Lending, which primarily addresses emerging real estate-related financing opportunities, and ResMac Inc., the company’s traditional mortgage origination, correspondent and servicing operation. REZYFi is currently licensed in 34 U.S. states, with plans to expand to all remaining states later this year.

REZYFi is positioned as one of first cannabis mortgage bankers in the U.S., while most traditional lenders are still reticent to serve the state-licensed cannabis industry.


REZYFi Lending

REZYFi Lending leverages a wide network to offer options such as 15- and 30-year fixed-rate loans, FHA loans, VA loans, reverse mortgages, jumbo loans and adjustable-rate mortgages.

Looking ahead, the company expects increased funding in marketing and loan agents to drive significant origination growth over the next two years, further supported by the planned launch of a high-margin cannabis division later this year.

ResMac Inc.

ResMac has been in operation for 13 years, having closed more than 20,000 loans for more than 15,000 clients. The company expects to accumulate $285 million in retail origination in 2023, alongside $250 million in wholesale origination for the same period. ResMac is further targeting $600 million in origination through its mortgage correspondent operations for 2023.

Through its ResMac subsidiary, REZYFi operates as a direct lender and originator of residential mortgages, with active mortgage correspondent and mortgage servicing operations. Through its correspondent segment, ResMac primarily purchases and aggregates residential mortgages from trusted third-party originators.

The company intends to harvest the database of customers within its mortgage servicing operations as an essential source of additional growth, especially relative to the new alternative residential loan programs being offered.

Corporate Strengths

  • Experience – REZYFi is led by a seasoned management team with significant expertise spanning a wide range of real estate and financing subsectors. The team also has extensive experience in the cannabis and hemp marketplace, which the company intends to leverage as it navigates the changing landscape of the cannabis industry while sourcing the best opportunities in the sector.
  • Network of Independent Brokers – Over the past five years, REZYFi has developed an extensive network of independent mortgage-related brokers and licensed loan officers. The company is currently training the network members on its new service offerings, with many already launching sales efforts. REZYFi believes this network will be a vital asset moving forward as other firms in the sector terminate relationships in the face of slowing mortgage business in a rising interest rate environment.
  • Proprietary Technology – REZYFi has invested heavily in designing, building and implementing proprietary automated/machine learning technology to shorten loan processing timeframes and increase efficiencies, allowing it to operate its legacy business at staffing levels meaningfully below those of its competitors.

Market Overview

REZYFi’s diversified approach to the real estate lending sector positions it to capitalize on growth in multiple verticals in the years to come.

In the first quarter of 2022, lenders issued 2.71 million residential loans, with the average balance for a first mortgage climbing to a record high of $298,324 in 2021, according to the Mortgage Bankers Association. This trend is expected to continue, with Freddie Mac forecasting a 10.4 percent increase in home prices in 2022 and a 5.0 percent bump in 2023. Growth prospects in the cannabis industry paint a similar picture.

The National Association of Realtors® issued a report in April 2021 examining the correlation between cannabis legalization and real estate demand. In states where prescription and recreational cannabis use is legal, more than a third of surveyed agents reported an increase in demand for warehouses. Likewise, 23 percent of those surveyed reported an increase in demand for storefronts, and 28 percent observed increased demand for land. As other states look to join the 19 that have embraced full cannabis legalization, this rising demand could create an opportunity for REZYFi’s cannabis-focused initiatives.

In total, an analysis by market research firm Business Research Insights projects the global loan servicing market to reach a value of nearly $1.5 billion by 2028, up from $680.8 million in 2021. Those figures represent a CAGR of 11.0 percent during the forecast period of 2022-2028.

Management Team

John Vu, Esq., is CEO of REZYFi, Inc. He has more than two decades of experience in the mortgage and commercial banking industry. He has filled many senior and executive management positions in high-producing mortgage banks, including C-level assignments. He has also served as general counsel for a nationally associated commercial bank. Mr. Vu brings considerable cannabis industry expertise to REZYFi. He has served as a corporate attorney to multiple cannabis cultivators, manufacturers and retailers.

Ji Ji Zhang, Esq., is CFO of REZYFi, Inc. He is a multifaceted entrepreneur who owns a law firm, a portfolio of hotels and a high-producing mortgage bank. Mr. Zhang is also an investor in the development of a cannabis business park. He brings more than five years of experience in mortgage banking to REZYFi, having developed Freddie Mac and HUD licenses and amassed a managed portfolio valued at over $300 million.

Kevin Heckemeyer is President of REZYFi, Inc. He has more than 25 years of experience in mortgage banking. He has built and sold several high producing mortgage businesses. In his current roles with ResMac, he is responsible for production and operations.

Spencer Dang is Chief Credit Officer of REZYFi, Inc. He has more than a decade of experience in mortgage operations. He is a direct endorsement underwriter for HUD and has specialized in non-QM underwriting. Under his watch as an underwriter, he has never had a single repurchase.

Recent News


QSAM Biosciences Inc. (OTCQB: QSAM)

The QualityStocks Daily Newsletter would like to spotlight QSAM Biosciences Inc. (OTCQB: QSAM).

Researchers at St. Jude’s Children Research Hospital have conducteda new study looking into drug sensitivity among patients with acute lymphoblastic leukemia across a varietyof genetic subtypes. Acute lymphoblastic leukemia is a common childhood cancer that affects white blood cells. It isestimated that roughly 98% of children suffering from this cancertype will experience remission after a few weeks of treatment. Ofthis number, almost 90% will be cured. Current treatments for acutelymphoblastic leukemia are risk adapted, which means thatchemotherapy is based on leukemia genomics, clinical features andthe extent of minimal residual disease.The researchers’ objective was to examine the pharmacogenomics ofacute lymphoblastic leukemia by looking into how the cancer cellsresponded to different therapies. Pharmacogenomics refers to thestudy of the ways an individual’s genetic characteristics affecttheir body’s response to drugs. With companies such as QSAM Biosciences Inc. (OTCQB: QSAM) also heavily focused on furthering the quest for better cancertreatments, it may not be long before major paradigm shifts areregistered in the realm of cancer care.

QSAM Biosciences Inc. (OTCQB: QSAM) is a clinical stage biotechnology company focused on bringing to market targeted therapeutic radiopharmaceuticals. The company is committed to advancing the fight against cancer through the discovery, development and delivery of effective treatment options for adult and pediatric patients.

QSAM Biosciences was founded in 2020 by Executive Chairman Dr. C. Richard Piazza and CEO Douglas Baum. It is headquartered in Austin, Texas.


CycloSam®, QSAM Biosciences’ initial technology, is a clinical-stage bone targeting radiopharmaceutical invented by world-renowned scientists at IsoTherapeutics Group LLC. By leveraging a patented, low specific activity form of Samarium-153 (resulting in far less undesirable europium impurity) and what management believes to be a superior chelating agent in DOTMP, CycloSam is designed to selectively target sites of high bone mineral turnover to deliver a prescribed tumor-killing dose of radiation to the bone tumor sites while minimizing radiation exposure to nearby healthy tissue. These parameters are currently being tested in an FDA-cleared clinical trial.

CycloSam® has been shown in laboratory testing to cause significantly less (30x less) buildup of long-lived radionuclidic impurities than prior FDA-approved drugs, which management believes will enable the ability to safely administer therapeutic doses via higher and multiple-dose regimens and effectively expand its potential clinical utility to therapeutic uses in areas of high unmet medical needs.

The indications for CycloSam® currently being evaluated by QSAM Biosciences include:

  • Metastatic Bone Cancers – On April 28, 2022, QSAM Biosciences announced that the first patient had commenced treatment in its clinical trial evaluating CycloSam in patients with metastatic bone cancer. As noted in the release, the study is a Phase 1 open-label, dose-escalation trial to evaluate the safety, tolerability, dosimetry, and preliminary efficacy of CycloSam®.
  • Pediatric Osteosarcoma/Ewing’s Sarcoma – On February 2, 2022, the company announced that the U.S. FDA has granted Rare Pediatric Disease Designation to CycloSam for the treatment of osteosarcoma. Combined with a previously granted orphan drug designation for osteosarcoma received in 2021, this milestone “may allow QSAM to potentially bring CycloSam® to market more rapidly through additional incentives and eligibilities,” according to CEO Douglas Baum.
  • Bone Marrow Ablation – In a 2020 single patient Investigational New Drug (IND) study, an investigator concluded that high-dose CycloSam® can be administered safely to ablate bone marrow in advance of a stem cell transplant with no apparent renal toxicity and no unexpected adverse events attributable to the drug.

QSAM Biosciences’ preclinical and clinical development pipeline is supported by a strong IP portfolio. The company has secured 14 patents across three distinct patent families spanning the U.S., Japan, Canada and the European Union.

Market Outlook

Through its ongoing development of CycloSam®, QSAM Biosciences is targeting multiple large and underserved market opportunities. According to the American Cancer Society, roughly 400,000 new cases of malignant bone metastasis are diagnosed annually in the U.S. alone. Additionally, QSAM will pursue indications for osteosarcoma and Ewing’s sarcoma that are the most common primary malignancies of bone tissues in children.

Despite this pressing need, the current standard of care for bone cancer is aggressive and suboptimal, leading to marginal success with significant side effects and poor long-term survival prognosis. As a result, QSAM Biosciences estimates a sizable market opportunity for its development pipeline.

  • Bone Metastasis has an estimated total addressable market of $20 billion in the U.S. based on total new cases and comparable drug pricing.
  • Osteosarcoma/Ewing’s Sarcoma have a total addressable market of roughly $125 million in the U.S. based on approximately 1,000 new cases in 2021.
  • The total addressable market for Bone Marrow Ablation is projected at $1 billion, with an estimated 32,000 procedures completed annually.

The company anticipates that the ability to administer CycloSam® for higher and multiple-dose regimens may expand its clinical utility for therapeutic uses in additional areas of high unmet medical needs.

Management Team

QSAM Biosciences is led by an experienced management team and board with an extensive record of FDA approvals, big pharma partnerships and M&A transactions.

Dr. C. Richard Piazza is the Executive Chairman of QSAM Biosciences. Since 2017, he has also served as President and CEO of IGL Pharma Inc., the licensor of CycloSam®, and as a consultant to IsoTherapeutics Group LLC, the inventors of the technology. Dr. Piazza also currently serves on the board of directors of NovaScan LLC, a privately held cancer detection and diagnostics company. He has more than 48 years of health care experience in both medical devices and pharmaceutical/biotech and has led several technology companies to market success, including numerous FDA approvals in both sectors. Dr. Piazza obtained a BS in Economics and a BS in Speech Pathology from the State University of New York and an MA & PhD in Economics from the University of Buffalo and Leeds University.

Douglas R. Baum is the company’s CEO and Director. He brings to QSAM Biosciences over 30 years of experience in the bioscience and biotech industries, including development, FDA/EMA approval and commercialization of multiple drugs and medical devices. Mr. Baum has overseen 15 product approvals through the FDA and EMA and raised over $85 million in capital to fund breakthrough technologies. From 2017 to 2020, he consulted with multiple medical schools and biotech and pharmaceutical companies, and, from 2012 to 2017, he served as President, Chief Executive Officer and Director of Xeris Pharmaceuticals Inc. Mr. Baum holds a Master of Science in Technology Commercialization and a BBA in International Business and Marketing from the University of Texas.

Adam King is the CFO of QSAM Biosciences. He is also the Founder and CEO of King Consulting Group, where he provides a range of financial and reporting services for clients. Before founding King Consulting Group in January 2021, Mr. King was the CFO for Netsertive, a venture-backed digital marketing company. From 2016 to 2018, he was the Office Managing Audit Director for BDO’s Greenville, South Carolina, office, in addition to serving as Audit Director in Raleigh, North Carolina, and Boston, Massachusetts. While at BDO, Mr. King worked with various clients, from tech and life science start-ups to billion-dollar publicly traded companies. He holds a Bachelor of Science in Accounting from Elon University and is a CPA in Raleigh, North Carolina.

QSAM Biosciences Inc. (OTCQB: QSAM), closed Thursday's trading session at $4.35, off by 13%, on 1,107 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $3.50/$14.00.

Recent News

Golden Matrix Group Inc. (NASDAQ: GMGI)

The QualityStocks Daily Newsletter would like to spotlight Golden Matrix Group Inc. (NASDAQ: GMGI).

Golden Matrix Group (NASDAQ: GMGI) is a developer, licensor and global operator of online gaming andeCommerce platforms, systems and gaming content. The company todayannounced its entry into a definitive acquisition agreementpursuant to which it has agreed to acquire MeridianBet Group andits related companies in a cash and stock transaction valued atapproximately $300 million. MeridianBet is Southeast Europe’sleading business-to-consumer (“B2C”) sports betting and gaminggroup with headquarters in Malta, operating in multiple marketsacross Europe, Africa and Latin America. “We are thrilled toannounce our entry into a purchase agreement with the shareholdersof MeridianBet Group. We believe that this acquisition will provideus entry into a well-established and highly scalable B2C verticalin new markets outside of our core markets,” said Brian Goodman,CEO of Golden Matrix. “MeridianBet Group appealed to us with itsproven business model that emphasizes organic growth, resilience toexternal economic factors, and exceptional products and technology.We are pleased to be on the path to completing this acquisition andlook forward to strengthening and growing our position in theglobal online betting and gaming industry, expanding into newregulated markets, and maintaining our ongoing drive to scale thebusiness as a whole at a rapid growth rate. MeridianBet Group’sregional market strength, brand awareness and proprietarytechnology solutions across the enlarged group are also expected tofurther accelerate our growth and expansion into new territories.”

To view the full press release, visit

Golden Matrix Group Inc. (NASDAQ: GMGI), based in Las Vegas, Nevada, is an established gaming technology company that develops and owns online gaming IP and builds turnkey online casino solutions for gaming operators as well as configurable and scalable white-label gaming platforms for international customers, located primarily in the Asia-Pacific region. GMGI’s gaming IP includes tools for marketing, acquisition, retention and monetization of users. The company’s platform can be accessed through both desktop and mobile applications.

GMGI’s sophisticated software automatically declines any gaming or redemption requests from within the United States, in strict compliance with U.S. law.

Golden Matrix, through a subsidiary, also runs a pay-to-enter prize competition in the United Kingdom and Ireland.

The company’s shares began trading on the Nasdaq under the symbol ‘GMGI’ on March 17, 2022. Golden Matrix shares were previously traded on the OTCQX Best Market.

For the quarter ended January 31, 2022, the company reported revenue of $8.88 million, an increase of 355% over the same quarter one year earlier. Net income for the three-month period was $349,379, up from $52,158 a year earlier. It was the company’s 14th consecutive profitable quarter.

In December 2021, Golden Matrix announced it had entered into a purchase agreement to acquire a controlling ownership interest in UK-based RKingsCompetitions Ltd., one of Ireland’s and the United Kingdom’s leading independent online competition companies. RKings presents customers with paid and free entry routes to competitions that offer a range of prizes, including residential properties, luxury and exotic motor vehicles, holiday packages, technology packages and cash. The competitions are currently open only to residents of Ireland and the United Kingdom. Golden Matrix acquired an 80% ownership interest in RKings for cash and stock. The company also secured an option to purchase the remaining 20 percent interest of RKings, subject to certain requirements.

In March 2022, Golden Matrix announced it had applied for a Mexican gaming permit and, once approved, expects to offer online gaming in Mexico as well as roll out the RKings tournament business globally.


Golden Matrix Group develops fully operational online casino turnkey solutions as well as highly modular, configurable and scalable gaming platforms for its international customers in an effort to promote user acquisition, engagement, retention and monetization. The provided white label gaming platform is unparalleled in both mobile and desktop website deployment, proving compatible throughout all major operating systems and web browsers. In addition, the platform enhances the client’s ability to cater to various gaming scenarios including but not limited to transaction management and a range of loyalty and reward programs. Moreover, user engagement is optimized through the ability to accommodate both free and paid games.

The company’s GM-X System (and recently its next generation GM-Ag System) is considered the industry standard, granting access to over 10,000 games from more than 25 game providers. Through the GM-X System, Golden Matrix offers the industry’s most extensive game portfolio. The company’s gaming partners dominate the global online gaming market to deliver innovative games and premium brand titles. The GM-X System offers payment gateways that integrate with third party platforms or digital wallets. It supports all major currencies and offers multiple language options. The system’s data analytics provide the operator with a 360-degree view of the gaming platform’s performance.

GMGI currently supports over 500 unique casino brands and over 6 million players.

Market Outlook

Online gaming and sports betting sites and apps are increasingly taking market share from traditional location-based casinos. Widespread internet service availability and increasing use of mobile phones for playing online games from homes and public places is driving the market, according to a report from Grand View Research. In addition, factors such as easy access to online gambling, legalization and cultural approval, corporate sponsorships, and celebrity endorsements are also contributing to market growth. The growing availability of cost-effective mobile applications across the globe is further expected to fuel market growth.

This trend is only expected to accelerate as millennials reach their peak earning years and Gen Z youth begin to complete their education and move into careers. These generations are completely comfortable with online recreation, and with using technology like digital wallets and digital gameplay that underpins online gaming.

The global online gambling market was valued at $53.7 billion in 2019 and is expected to grow at a CAGR of 11.5% from 2020 to 2027 to reach a value of $127.3 billion, according to Grand View Research, with much of the growth expected from the U.S. and Asia. Even Europe, the most mature gaming market, is expected to grow at a rate of 20-25% year-over-year.

Management Team

Brian Goodman is CEO of Golden Matrix Group. He has more than 20 years of diverse senior management experience and business development roles within the technology and internet gaming industries. He has a tertiary science qualification as well as a marketing and sales background. His previous roles have been entrepreneurial and include CEO and senior management positions in smaller organizations, which he founded or in which he held equity, as well as multinational organizations.

Cathy Feng is COO at Golden Matrix. She is a co-founder of GMGI and holds a Master of Commerce degree. She has 10 years of experience as a financial officer in the technology and internet gaming industries. In past management positions, she interpreted, analyzed and presented financial and operation information to facilitate business decisions, grow companies and resolve complex problems. In addition, she has skills in marketing, business development, leadership and strategic planning.

Omar Jimenez is CFO and Chief Compliance Officer at GMGI. Prior to joining the company, he was CFO and COO of Alfadan Inc., a supplier of marine outboard engines. He has held senior financial management and operational positions at public and private companies including NextPlay Technologies, American Leisure Holdings, US Installation Group and Onyx Group. He holds various accounting professional certifications, including CPA and CPCU, and degrees in finance, accounting and business.

Henry Zhang is Chief Technology Officer at Golden Matrix. He oversees all aspects of development, integration and deployment of GMGI’s technology systems. He plays a key role in evolving GMGI’s technology business to lead and shape the industry. He is responsible for developing and scaling new businesses, including online gaming, eSport and P2P Systems. He was instrumental in launching the GM-X system and has been with the company for more than six years.

Golden Matrix Group Inc. (NASDAQ: GMGI), closed Thursday's trading session at $3.8, off by 7.0905%, on 115,357 volume. The average volume for the last 3 months is 115,345 and the stock's 52-week low/high is $1.89/$10.72.

Recent News

Cybin Inc. (NEO: CYBN) (OTC: CYBN)

The QualityStocks Daily Newsletter would like to spotlight Cybin Inc. (NEO: CYBN) (NYSE American: CYBN).

Cybin (NYSE American: CYBN) (NEO: CYBN) is a biotechnology company focused on progressing Psychedelics toTherapeutics(R). The company today announced that it has selectedGeneralized Anxiety Disorder (“GAD”) with or without majordepressive disorder (“MDD”) as the target indication for CYB004 —its proprietary deuterated N, N-dimethyltryptamine (“DMT”)molecule. “Based on preclinical data, CYB004 has shown promise intreating anxiety disorders. About half of people suffering fromdepression are also burdened with GAD, which makes the need formore effective treatment options for GAD even more urgent,” saidCybin CEO Doug Drysdale. “Since the pandemic, the prevalence ofdepression and anxiety has been significantly elevated, and we areoptimistic that through our current development programs, Cybin hasthe potential to provide innovative therapeutics to alleviate themental suffering that so many people experience worldwide. Weremain focused on the opportunity that CYB004, as a new chemicalentity, may be able to provide a new path toward mental healing.”

To view the full press release, visit

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) is a Canada-based life sciences company focused on the pharmaceutical development of psychedelic products, as well as the functional mushroom market.

The early-stage company boasts an experienced management team featuring industry veterans from pharmaceutical and consumer product backgrounds who have run multiple clinical trials and collectively helped facilitate billions of dollars in product revenues. The team is dedicated to the development of products and protocols within the psychedelic, pharmaceutical and nutraceutical industries.

In particular, Cybin aims to further build upon and expand its intellectual property (IP) portfolio, which is structured around unique psilocybin delivery mechanisms that target a number of different therapeutic indications. In addition, the company has dedicated itself toward furthering its research and IP within the fields of synthetic compounds, extraction methods, the isolation of chemical compounds, new drug formulations and protocol regimes.

Serenity Life Sciences & Natures Journey Inc.

The company’s business model is centered around its two core subsidiaries, Serenity Life Sciences and Natures Journey Inc., which comprise Cybin’s two-pronged approach toward delivering fungi-derived psychedelic and medicinal products.

Serenity Life Sciences is focused on furthering research and development of psilocybin-based medications. Psilocybin is found in certain species of mushrooms and is a non-habit forming, naturally occurring psychedelic compound. Research into psilocybin has shown positive results for the treatment of depression, anxiety, PTSD, addiction, eating disorders, ADHD and other indications.

Natures Journey Inc. operates the Journey brand, which specializes in developing proprietary medicinal mushroom products that target and promote mental wellness, immune boosting detoxification and overall general health and wellbeing.

Partnership with the Toronto Centre for Psychedelic Science (TCPS)

Staying true to its axiom of being a research-first medicinal mushroom life sciences company, Cybin recently announced its entry into a strategic partnership with the Toronto Centre for Psychedelic Science (TCPS), with the goal of furthering its ongoing psilocybin research efforts and expanding Cybin’s psilocybin IP portfolio (

“While there is evidence to support psilocybin as a treatment for certain indications, the Toronto Centre for Psychedelic Science is taking a clinical approach to prove or disprove the safety and efficacy of psilocybin-based microdosing through an open science approach,” Paul Glavine, CEO of Cybin, stated in a news release.

“We are excited to join forces with Cybin and to offer our expertise. A number of firms had approached TCPS, but Cybin demonstrated a superior commitment to high-quality research and integrity in product development. Our high standards for scientific rigor and transparency will find a fitting home within the culture Cybin is cultivating in Canada and abroad,” Thomas Anderson, co-founder of the Toronto Centre for Psychedelic Science, added.

Journey’s Product Monetization & Market Potential for Nutraceutical Supplements

Although Cybin is at the forefront of companies seeking to conduct clinical trials aimed at gaining regulatory approval for psilocybin and other psychedelic products, the company has also placed a great deal of emphasis on generating meaningful revenue from its very outset.

Cybin’s Journey brand has is launching a range of supplements comprised of popular fungi-derived ingredients such as Reishi, Lion’s Mane and Cordyceps. Purported to aid focus and concentration while promoting neurogenesis, Journey’s range of nutraceutical products provides Cybin with a crucial foothold within the non-psychedelic legal supplement market, which is valued at over $25 billion globally and growing at a 9% year-over-year rate.

Pharmaceutical Psychedelics

In addition to the company’s range of non-psychedelic supplements, Cybin has plans to carry out a clinical trial with a new delivery system for its psilocybin-based medications later this year. Ultimately, the company aims to enter into technology transfer agreements with global pharmaceutical companies after phase 1 & phase 2 clinical trials are complete in order to accelerate regulatory approvals in major indications in global markets with entire lifecycle product management.

With products such as psilocybin truffles already legal in nations such as the Netherlands, Jamaica and Bulgaria, Cybin has positioned itself to capitalize on an eventual legalization of psychedelic mushroom-derived products in the future. Working within a regulatory environment with strong similarities to that which dealt with cannabis prior to the industry’s eventual legalization by the Canadian government in 2018, Cybin is laying the groundwork for the moment pharmaceutical psychedelics gain acceptance in North America and abroad.

Amalgamation Agreement and Financing

Cybin recently announced its entry into an amalgamation agreement dated June 26, 2020, with Clarmin Explorations Inc. (TSX.V: CX) and 2762898 Ontario Inc., a wholly owned subsidiary of Clarmin ( Completion of the transactions contemplated in the amalgamation agreement will result in the reverse takeover of Clarmin by Cybin.

In connection with the proposed transaction, Cybin plans to complete a “best-efforts” brokered private placement of subscription receipts of Cybin, with a syndicate of agents co-led by Stifel Nicolaus Canada Inc. (Stifel GMP) and Eight Capital, to raise a minimum of C$14 million ($10 million) and a maximum of C$21 million ($15 million), with a 15% agents’ option.

To date, Cybin has raised approximately C$10,400,000 through an initial financing round and its series A financing round.

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), closed Thursday's trading session at $0.4643, off by 10.4705%, on 4,897,669 volume. The average volume for the last 3 months is 4.81M and the stock's 52-week low/high is $0.2649/$1.16.

Recent News

Sharing Services Global Corporation (SHRG)

The QualityStocks Daily Newsletter would like to spotlight Sharing Services Global Corporation (SHRG).

Sharing Services Global (OTCQB: SHRG), a publicly traded company dedicated to maximizing shareholdervalue through the acquisition and development of innovativecompanies, products and technologies, has inked a binding letter ofintent (“LOI”) with American Wealth Mining Corporation (OTC: HIPH) to franchise the first HAPI Café location in New York City. SHRGis the master franchisor of HAPI Café in North America. Accordingto the announcement, the companies plan to complete the transactionby the end of this month. In addition to the New York Citylocation, American Wealth Mining anticipates opening 20 more HAPICafes in New York state in the next 18 months. HAPI Café is workingto have more than 200 locations throughout the United States inthat same time period. The HAPI Cafe format features a lifestylecafé outlet designed to transform the way people eat, work andlive, by providing a combination of health, fitness, work andLeisure services under one roof “The company is excited for itsfirst HAPI Cafe location in New York,” said American Wealth MiningCEO Ryan Fishoff in the press release. “This is a milestoneachievement for AWM as we are positioning the company to meet thestrategic goal that we set back in August to open 20 cafes in NewYork State over the next 18 months. The HAPI Cafe concept is acentral part of the company’s shift towards ‘wealth mining’; theselocations will be centers of innovation in which customers will beexposed to the future of finTech, education, wellness, crypto,health and wealth that meet the demands of the 21st-centuryconsumer. The cafes will be a significant revenue driver for thecompany, targeting to add over seven figures once our goal of 20locations is achieved.”

To view the full press release, visit

Sharing Services Global Corporation (SHRG), formerly Sharing Services Inc., is a diversified company dedicated to maximizing shareholder value, operating through two primary subsidiaries: Elepreneurs Holdings, a direct-selling company, and Elevacity Holdings, a products company. Headquartered in Plano, Texas, SHRG markets and distributes Elevate-branded health and wellness products through an independent sales force of distributors called Elepreneurs.

Proprietary Products

SHRG’s current exclusive Elevate product offerings are marketed under the Elevacity brand, so named to signify the company’s commitment to elevating lives.

The Elevate health and wellness product line consists of nutraceutical products that SHRG refers to as D.O.S.E., which stands for dopamine, oxytocin, serotonin and endorphins – all of which are key hormones proven to promote happiness and well-being.

Elevacity brand products are carefully formulated, chosen and designed to support a single objective: elevate the happiness and well-being of the consumer.

Global Network of Elepreneurs

Elevacity products are shared and sold by a growing international network of home-based entrepreneurs, called Elepreneurs, operated by Elepreneurs Holdings. This SHRG subsidiary provides basic and advanced programs for both new and experienced entrepreneurs who are focusing on their direct-sales careers.

SHRG’s high-performing independent sales force follows the company’s Blue Ocean selling strategy, an approach that encourages individuals to seek new markets, lead, and to “stop competing and start creating.” The Blue Ocean strategy is based on the book, “Blue Ocean Strategy,” written by Professor Renée Mauborgne, who notes that “the lesson here is that the best defense is offense, and the best offense… is to make a blue ocean shift and create your own blue ocean.”

Following this selling strategy, SHRG’s Elepreneurs are taught that, rather than competing directly in a competitive, direct-selling market, they should focus on making competitors irrelevant and succeeding in an uncontested marketplace.

In addition, SHRG’s Elepreneurs use the interactive, video-based VERB sales-marketing platform developed by Verb Technology Company Inc. The app utilizes proprietary interactive video data collection and analysis technology and provides next-generation customer relationship management, lead generation, and video marketing software applications.

Continued Momentum as Industry Leader

These selling strategies have resulted in sharp and consistent revenue gains. In the company’s 10-Q filed with the SEC for the three months ended Oct. 31, 2019, SHRG reported sales of $38.8 million for fiscal Q2 2019, an increase of 116% over sales of $17.9 million reported for the comparable quarter of 2018. Consolidated gross profit jumped by $16.2 million to $27.4 million for the same period compared to Q2 2018.

SHRG’s consolidated operating earnings were $3.9 million in the fiscal quarter ended Oct. 31, 2019, compared to $866,802 for the comparable period the prior year. Consolidated gross margin also grew 70.9% for the three months ended Oct. 31, 2019, compared to 62.2% the prior year.

These numbers are continuing a trend established over the past two years. In fiscal Q1 2019, SHRG achieved revenues of $35.4 million, more than double that of the comparable period in 2018. Even earlier, the company reported sales of $85.9 million for fiscal year ended April 30, 2019. This represents a nine-fold increase, or $77.5 million jump, over the company’s revenues of $8.4 million the prior year.

These numbers bring SHRG’s sales revenues since December 2017 — when the company’s Elevate product line was released — to an impressive cumulative total of $169 million.

Preparing for Success

SHRG is well prepared to continue and accommodate for this growth. The company recently expanded its corporate footprint by moving to a 10,000-square-foot facility in Plano, Texas, that offers ample room to expand as the company grows and flourish. The larger corporate locale provides space for a growing customer service department, product fulfillment, opportunity and training rooms, as well as a video production suite.

In addition, the company has a seasoned, expert leadership team in place, led by John “JT” Thatch. Thatch was appointed president and CEO of SHRG in March 2018, bringing to the company his expertise obtained from successfully starting, owning and operating several businesses in various industries. His experience with corporate growth, acquisitions, financing and negotiation in fast-paced and flexible environments will significantly assist SHRG as the company aims to expand and increase revenues.

469.304.9400 x 201

Sharing Services Global Corporation (SHRG), closed the day's trading session at $1.01, up 23.17%, on 276,351 volume with 217 trades. The average volume for the last 3 months is 279,074 and the stock's 52-week low/high is $0.27/$2.54.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.